<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for melanoma in situ, including lentigo maligna - Tzellos, T - 2014 | Cochrane Library</title> <meta content="Interventions for melanoma in situ, including lentigo maligna - Tzellos, T - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010308.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for melanoma in situ, including lentigo maligna - Tzellos, T - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010308.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010308.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for melanoma in situ, including lentigo maligna" name="citation_title"/> <meta content="Thrasivoulos Tzellos" name="citation_author"/> <meta content="Faculty of Health Sciences, University Hospital of North Norway" name="citation_author_institution"/> <meta content="ltzellos@googlemail.com" name="citation_author_email"/> <meta content="Athanassios Kyrgidis" name="citation_author"/> <meta content="Simone Mocellin" name="citation_author"/> <meta content="An‐Wen Chan" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Pierluigi Pilati" name="citation_author"/> <meta content="University of Padova" name="citation_author_institution"/> <meta content="Zoe Apalla" name="citation_author"/> <meta content="Hospital of Skin and Venereal Diseases" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD010308.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/12/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010308.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010308.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010308.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aminoquinolines [administration &amp; dosage]; Antineoplastic Agents [*administration &amp; dosage]; Antineoplastic Combined Chemotherapy Protocols [administration &amp; dosage]; Combined Modality Therapy [methods]; Hutchinson's Melanotic Freckle [*therapy]; Imiquimod; Melanoma [*therapy]; Melanoma, Cutaneous Malignant; Nicotinic Acids [administration &amp; dosage]; Randomized Controlled Trials as Topic; Skin Neoplasms [*therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010308.pub2&amp;doi=10.1002/14651858.CD010308.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tlnpj831";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010308\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010308\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010308.pub2",title:"Interventions for melanoma in situ, including lentigo maligna",firstPublishedDate:"Dec 19, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010308.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010308.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010308.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010308.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010308.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010308.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010308.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010308.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010308.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010308.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5466 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010308.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/appendices#CD010308-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/table_n/CD010308StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/table_n/CD010308StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for melanoma in situ, including lentigo maligna</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Thrasivoulos Tzellos</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0003">Athanassios Kyrgidis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0004">Simone Mocellin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0005">An‐Wen Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0006">Pierluigi Pilati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information#CD010308-cr-0007">Zoe Apalla</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information/en#CD010308-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 December 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010308.pub2">https://doi.org/10.1002/14651858.CD010308.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010308-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010308-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010308-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010308-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010308-abs-0001" lang="en"> <section id="CD010308-sec-0001"> <h3 class="title" id="CD010308-sec-0001">Background</h3> <p>Malignant melanoma is a form of skin cancer associated with significant mortality once it has spread beyond the skin. Melanoma in situ (MIS) is the earliest histologically recognisable stage of malignant melanoma and represents a precursor of invasive melanoma. Lentigo maligna (LM) represents a subtype of pre‐invasive intraepidermal melanoma associated specifically with chronic exposure to ultraviolet (UV) radiation. Over the past two decades, the incidence of MIS has increased significantly, even more than the invasive counterpart. There are several treatment options for MIS, but no consensus exists on the best therapeutic management of this condition. </p> </section> <section id="CD010308-sec-0002"> <h3 class="title" id="CD010308-sec-0002">Objectives</h3> <p>To assess the effects of all available interventions, surgical and non‐surgical, for the treatment of melanoma in situ, including LM. </p> </section> <section id="CD010308-sec-0003"> <h3 class="title" id="CD010308-sec-0003">Search methods</h3> <p>We searched the following databases up to November 2014: the Cochrane Skin Group Specialised Register, CENTRAL in <i>The Cochrane Library</i> (2014, Issue 10), MEDLINE (from 1946), Embase (from 1974), LILACS (from 1982), African Index Medicus (from inception), IndeMED of India (from inception), and Index Medicus for the South‐East Asia Region (IMSEAR) (from inception). We scanned the references of included and excluded studies for further references to relevant trials and searched five trials registries. We checked the abstracts of major dermatology and oncology conference proceedings, and we shared our lists of included and excluded studies with industry contacts and other experts in the field of melanoma to try to identify further relevant trials. </p> </section> <section id="CD010308-sec-0004"> <h3 class="title" id="CD010308-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCT) on the management of MIS, including LM, that compared any intervention to placebo or active treatment. We included individuals, irrespective of age and sex, diagnosed with MIS, including LM, based on histological examination. </p> </section> <section id="CD010308-sec-0005"> <h3 class="title" id="CD010308-sec-0005">Data collection and analysis</h3> <p>Two authors independently evaluated possible studies for inclusion; extracted data from the included study using a standard data extraction form modified for our review; assessed risk of bias; and analysed data on efficacy, safety, and tolerability. They resolved any disagreements by discussion with a third author. We collected adverse effects information from included studies. </p> </section> <section id="CD010308-sec-0006"> <h3 class="title" id="CD010308-sec-0006">Main results</h3> <p>Our search identified only 1 study eligible for inclusion (and 1 ongoing study in active recruitment stage), which was a single centre, open label, parallel group, 2‐arm RCT with 90 participants, who had 91 histologically proven LM lesions. </p> <p>Forty‐four participants, with 44 LM lesions, were treated with imiquimod 5% cream 5 days per week plus tazarotene 0.1% gel 2 days/week for 3 months, and 46 participants, with 47 LM lesions, were treated with imiquimod 5% cream 5 days per week for 3 months. Two months after cessation of topical treatment, the initial tumour footprint was excised using 2 mm margins via a staged excision. This study was open label, and analysis was not intention‐to‐treat, leading to a high risk of incomplete outcome data. </p> <p>Our primary outcome 'Histological or clinical complete response' was measured at 5 months in 29/44 participants (66%) treated with imiquimod plus tazarotene (combination therapy) and 27/46 participants (59%) treated with imiquimod (monotherapy). The difference was not statistically significant (risk ratio (RR) 1.12, 95% confidence interval (CI) 0.81 to 1.55, P value = 0.48). </p> <p>With regard to our secondary outcomes on recurrence and inflammation, after a mean follow up of 42 months, no local recurrences were observed among complete responders. Difference in overall inflammation score between the 2 groups was significant (mean difference (MD) 0.6, 95% CI 0.2 to 1, P value = 0.004), with the mean overall inflammation score being significantly higher in the combination group. </p> <p>The study authors did not clearly report on side‐effects. Because of adverse effects, there was a dropout rate of 6/44 participants (13.7%) in the combination group compared with 1/46 (2.2%) in the imiquimod monotherapy group (due to excessive inflammation) before the cessation of topical treatment (first 3 months), but this was not statistically significant (RR 6.27, 95% CI 0.79 to 50.02, P value = 0.08). </p> </section> <section id="CD010308-sec-0007"> <h3 class="title" id="CD010308-sec-0007">Authors' conclusions</h3> <p>There is a lack of high‐quality evidence for the treatment of MIS and LM.</p> <p>For the treatment of MIS, we found no RCTs of surgical interventions aiming to optimise margin control (square method, perimeter technique, 'slow Mohs', staged radial sections, staged "mapped" excisions, or Mohs micrographic surgery), which are the most widely used interventions recommended as first‐line therapy. The use of non‐surgical interventions in selected cases (patients with contraindications to surgical interventions) may be effective and may be considered preferable for experienced providers and under close and adequate follow up. </p> <p>For the treatment of LM, we found no RCTs of surgical interventions, which remain the most widely used and recommended available treatment. The use of non‐surgical interventions, such as imiquimod, as monotherapy may be effective and may be considered in selected cases where surgical procedures are contraindicated and used preferentially by experienced providers under close and adequate follow up. The use of topical therapies, such as 5‐fluorouracil and imiquimod, as neoadjuvant therapies warrants further investigation. There is insufficient evidence to support or refute the addition of tazarotene to imiquimod as adjuvant therapy; the current evidence suggests that it can increase topical inflammatory response and withdrawal of participants because of treatment‐related side‐effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010308-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010308-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD010308-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD010308-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010308-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010308-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010308-abs-0002" lang="en"> <h3>Interventions for treatment of melanoma in situ, including lentigo maligna</h3> <p><b>Background</b> </p> <p>Melanoma in situ (MIS) is the earliest stage of malignant melanoma. Over the past two decades, the incidence of MIS has increased. Lentigo maligna (LM) is a subtype of pre‐invasive melanoma associated with chronic exposure to ultraviolet radiation, primarily affecting the head and neck. It accounts for 79% to 83% of all MIS tumours. Delayed recognition is common. </p> <p><b>Review question</b> </p> <p>What are the effects of surgical and non‐surgical treatments for MIS, including LM?</p> <p><b>Study characteristics</b> </p> <p>We identified one randomised controlled clinical trial (RCT) of the non‐surgical treatment of 90 people with LM: 44 were treated with imiquimod cream plus tazarotene gel, and 46 were treated with imiquimod cream for 3 months; these interventions were followed by staged excision after 2 months. We did not find any RCTs of surgical treatments. </p> <p><b>Key results</b> </p> <p>Of those treated with imiquimod and tazarotene, 66% had a complete response at 5 months compared with 59% of those treated with imiquimod alone. The addition of tazarotene to imiquimod did not lead to a clinically better response, and the people in this group had higher inflammation. There were more dropouts due to adverse effects in this group. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence is poor. With regard to the treatment of MIS, surgical interventions that aim to excise the tumour so that none of the tumour cells are in the margin are the most recommended interventions in non‐selected cases. The evidence does not support the use of non‐surgical interventions in selected cases (i.e., in elderly people with contraindications to surgical interventions). However, clinical centres may consider it where there is experience of this treatment and where close and adequate follow up can be undertaken. </p> <p>With regard to the treatment of LM, surgical interventions remain the most recommended available treatment. The evidence does not support the use of non‐surgical interventions, such as imiquimod, as a single therapy in non‐selected cases. It may be considered only in selected cases and in clinical centres with experience. The evidence so far does not support the use of imiquimod as a neoadjuvant (i.e., before surgery) therapy but warrants further investigation, in order to evaluate if use after surgery can minimise recurrence and if use before surgery of large lesions or difficult sites can help to achieve smaller surgical excisions. The evidence does not support addition of tazarotene to imiquimod as neoadjuvant therapy. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010308-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010308-sec-0111"></div> <h3 class="title" id="CD010308-sec-0112">Implications for practice</h3> <section id="CD010308-sec-0112"> <p>There is a lack of high‐quality evidence for the treatment of melanoma in situ and lentigo maligna. Regarding treatment of melanoma in situ, surgical interventions aiming to optimise margin control (square method, perimeter technique, 'slow Mohs', staged radial sections, staged "mapped" excisions, and Mohs micrographic surgery) are the most widely used interventions recommended as first‐line therapy, although randomised controlled trials of these interventions are missing. The use of non‐surgical interventions in selected cases (patients with contraindications to surgical interventions) may be effective and can be considered preferable for experienced providers and under close and adequate follow up. </p> <p>Regarding the treatment of lentigo maligna, surgical interventions remain the most widely used and recommended available treatment, although randomised controlled trials are lacking. The use of non‐surgical interventions, such as imiquimod as monotherapy, may be effective and may be considered in selected cases where surgical procedures are contraindicated and preferably for experienced providers under close and adequate follow up. The evidence does not support the use of topical therapies, such as 5‐fluorouracil and imiquimod, as neoadjuvant therapy, but warrants further investigation. There is insufficient evidence to support or refute the addition of tazarotene to imiquimod as adjuvant therapy; the current evidence suggests that it can increase the topical inflammatory response and lead to withdrawal of patients due to treatment‐related side‐effects. </p> </section> <h3 class="title" id="CD010308-sec-0113">Implications for research</h3> <section id="CD010308-sec-0113"> <p>Future studies regarding interventions for the treatment of melanoma in situ and lentigo maligna should be controlled; randomised; and where possible, blinded (particularly the outcome assessor). Adequate follow up to appropriately study important outcomes, such as recurrence rate, is of high importance. When non‐surgical topical interventions, such as imiquimod or retinoids, are compared, an appropriate vehicle can be used to enable blinding, which could lead to a more objective evaluation of these treatments. Future studies should also include a sample size calculation according to a specific clinically relevant outcome, such as complete response (for non‐surgical treatments) and local recurrence rate. Appropriately powered studies are needed. Multicentre studies are greatly needed to both increase sample size and assess variability between centres, especially for surgical interventions. </p> <p>Since neoadjuvant therapies aim to reduce morbidity, reduce excision margins, and increase treatment‐related quality of life, especially in specific subgroups such as the elderly, it is important that future studies include outcomes such as treatment‐related quality of life and participant satisfaction. Until now, they have been not addressed at all. All future trials should include and assess quality of life outcomes. Future studies must appropriately study and address reduction of excision margins. The use of topical agents, such as 5‐fluorouracil and imiquimod, as neoadjuvant treatments warrant further investigation, especially for outcomes such as reduction of morbidity, decrease of recurrence rate, and reduction of surgical excision margins. It is important that future studies use such outcomes. </p> <p>Current evidence does not prioritise the need for trials studying the combination of topical retinoid and imiquimod in the treatment of lentigo maligna. Studies of the use of imiquimod as monotherapy in those who are able to undergo surgery are not recommended. Non‐surgical topical interventions as monotherapy can be studied in those who decline surgery or for whom surgical treatment is contraindicated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010308-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010308-sec-0015"></div> <div class="table" id="CD010308-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with melanoma in situ, including lentigo maligna<br/> <b>Settings:</b> 1 academic centre in the US<br/> <b>Intervention:</b> imiquimod 5% cream with tazarotene 0.1% gel<br/> <b>Comparison:</b> imiquimod 5% cream alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Imiquimod 5% cream alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Imiquimod 5% cream with tazarotene 0.1% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome:</b> </p> <p><b>Histological complete response (intention‐to‐treat)</b> <br/> No residual LM in staged excision 2 months post‐treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>587 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b> <br/> (475 to 910) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.81 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome:</b> </p> <p><b>Histological complete response ( available‐case analysis)</b> <br/> No residual LM in staged excision 2 months post‐treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>659 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (593 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.9 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Discontinuation of treatment because of harms</b> <br/> Discontinuation of treatment due to adverse effects </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> <br/> (17 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.27</b> <br/> (0.79 to 50.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Inflammatory response (number of lesions with grade 2 or 3)</b> <br/> Grade 2 or 3 Inflammation² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>815 per 1000</b> <br/> (615 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b> <br/> (1.04 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Inflammatory response</b> </p> <p><b>(overall Inflammation score) for all participants</b> <br/> Mean grade of inflammation in each group² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall inflammation score (inflammatory response) for all participants in the intervention groups was <b>0.60 higher</b> <br/> (0.2 to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>GRADE = Grading of Recommendations Assessment, Development and Evaluation.<br/> LM = lentigo maligna.<br/> ¹Published evidence is limited to a single randomised trial.<br/> ²(0 indicates no inflammation; 1, pink; 2, red; and 3, the presence of erosions, oozing, or eschar). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010308-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010308-sec-0016"></div> <p>Please note that we have listed unfamiliar terms in <a href="#CD010308-tbl-0002">Table 1</a>. </p> <div class="table" id="CD010308-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Medical term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraepidermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>something confined within the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preinvasive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a malignant tumour that remains constricted in the epithelium, while the dermo‐epidermal junction preserves its integrity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eschar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a dry scab or slough formed on the skin as a result of a burn or by the action of a corrosive or caustic substance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a malignant tumour that breaks the dermo‐epidermal junction and invades the dermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lentigo maligna</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a subtype of preinvasive intraepidermal melanoma, associated specifically with chronic solar exposure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>an excipient or a menstruum, a substance, usually without therapeutic action, used as a medium to give bulk for the administration of medicines </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a genetically directed process of cell self‐destruction that is marked by the fragmentation of nuclear DNA. It is activated either by the presence of a stimulus or removal of a suppressing agent or stimulus, and is a normal physiological process eliminating DNA‐damaged, superfluous, or unwanted cells. It is a synonym for programmed cell death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actinic keratosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rough, scaly macule or patch of skin that it is considered precancerous and is associated with chronic sun exposure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lentigo senilis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a flat brownish, pigmented spot on the skin, due to increased deposition of melanin and an increased number of melanocytes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seborrheic keratosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a benign skin tumour that occurs singly or in clusters on the surface of the skin, is usually light to dark brown or black in colour, and typically has a warty texture often with a waxy appearance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a greater than 1 cm circumscribed area of discolouration on the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a small protein released by cells that has a specific effect on the interactions between cells, on communications between cells, or on the behavior of cells </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Innate immunity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>immunity that occurs naturally as a result of a person's genetic constitution or physiology and does not arise from a previous infection or vaccination </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the concealment of group assignment ‐ to either the treatment or control group ‐ from the knowledge of participants, investigators in a clinical trial, or both </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aggregates of tumour cells</p> </td> </tr> </tbody> </table> </div> <section id="CD010308-sec-0017"> <h3 class="title" id="CD010308-sec-0017">Description of the condition</h3> <p>Melanoma is one of the deadliest types of skin neoplasm (abnormal growth), resulting from the uncontrollable proliferation of malignant melanocytes (cells within the epidermis) (<a href="./references#CD010308-bbs2-0012" title="BichakjianCK ,  HalpernAC ,  JohnsonTM ,  Foote HoodA ,  GrichnikJM ,  SwetterSM ,  etal . Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. Journal of American Academy of Dermatology2011;65(5):1032‐47. [MEDLINE: 21868127] ">Bichakjian 2011</a>). </p> <p>Melanoma in situ (MIS) is the earliest histologically recognisable stage of malignant melanoma, and it is characterised by an increased number of atypical intraepidermal melanocytes (<a href="./references#CD010308-bbs2-0042" title="KingR , PageRN , GoogePB , MihmMC . Lentiginous melanoma: a histologic pattern of melanoma to be distinguished from lentiginous nevus. Modern Pathology2005;18(10):1397‐401. [MEDLINE: 15976811] ">King 2005</a>; <a href="./references#CD010308-bbs2-0074" title="TannousZS , LernerLH , DuncanLM , MihmMC , FlotteTJ . Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Human Pathology2000;31(6):705‐8. [MEDLINE: 10872664] ">Tannous 2000</a>). The disease is clinically relevant because it represents a precursor of invasive melanoma. Individuals diagnosed with melanoma in situ have a higher risk of developing invasive melanoma in their lifetime (<a href="./references#CD010308-bbs2-0058" title="Mocellin S , NittiD . Cutaneous melanoma in situ: translational evidence from a large population‐based study. Oncologist2011;16(6):896‐903. [MEDLINE: 21632457] ">Mocellin 2011</a>). Over the past two decades, the incidence of melanoma in situ has increased significantly, even more than the invasive counterpart (<a href="./references#CD010308-bbs2-0015" title="CharlesCA , YeeVS , DuszaSW , MarghoobAA , OliveriaSA , KopfA , et al. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists. Archives of Dermatology2005;141(6):723‐9. [MEDLINE: 15967918] ">Charles 2005</a>), which has led some authors to state that we are witnessing a kind of melanoma epidemic (<a href="./references#CD010308-bbs2-0011" title="Beddingfield FC . The melanoma epidemic: res ipsa loquitur. Oncologist2003;8(5):459‐65. [MEDLINE: 14530499] ">Beddingfield 2003</a>; <a href="./references#CD010308-bbs2-0058" title="Mocellin S , NittiD . Cutaneous melanoma in situ: translational evidence from a large population‐based study. Oncologist2011;16(6):896‐903. [MEDLINE: 21632457] ">Mocellin 2011</a>). </p> <p>Lentigo maligna (LM) represents a subtype of pre‐invasive intraepidermal melanoma associated specifically with chronic exposure to ultraviolet (UV) radiation, primarily affecting the head and neck region. It is the most prevalent melanoma in situ subtype, accounting for 79% to 83% of all melanoma in situ tumours (<a href="./references#CD010308-bbs2-0047" title="KvaskoffM , SiskindV , GreenAC . Risk Factors for Lentigo Maligna Melanoma Compared With Superficial Spreading Melanoma: A Case‐Control Study in Australia. Archives of Dermatology2012;148(2):164‐70. [MEDLINE: 22004881] ">Kvaskoff 2011</a>; <a href="./references#CD010308-bbs2-0054" title="McKennaJK , FlorellSR , GoldmanGD , BowenGM . Lentigo maligna/lentigo maligna melanoma: current stage of diagnosis and treatment. Dermatological Surgery2006;32(4):493‐504. [MEDLINE: 16681656] ">McKenna 2006</a>). </p> <p>Lentigo maligna melanoma (LMM) represents 4% to 15% of all melanomas (<a href="./references#CD010308-bbs2-0016" title="ClarkWH , ElderDE , VanHornM . The biologic forms of malignant melanoma. Human Pathology1986;17(5):443‐50. [MEDLINE: 3699806] ">Clark 1986</a>; <a href="./references#CD010308-bbs2-0054" title="McKennaJK , FlorellSR , GoldmanGD , BowenGM . Lentigo maligna/lentigo maligna melanoma: current stage of diagnosis and treatment. Dermatological Surgery2006;32(4):493‐504. [MEDLINE: 16681656] ">McKenna 2006</a>; <a href="./references#CD010308-bbs2-0055" title="McLeodM , ChoudharyS , GiannakakisG , NouriK . Surgical Treatments for Lentigo Maligna: A Review. Dermatologic Surgery2011; Vol. 37, issue 9:1210‐28. [MEDLINE: 21631635] ">McLeod 2011</a>). Its incidence is increasing in people older than 45 years, at a greater rate than for any other melanoma subtype (<a href="./references#CD010308-bbs2-0073" title="SwetterSM ,  BoldrickJC ,  JungSY ,  EgbertBM ,  HarvellJD . Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990‐2000. Journal of Investigative Dermatology2005;125(4):685‐91. [MEDLINE: 16185266] ">Swetter 2005</a>). Swetter et al report that regional (California) and national data suggest an increasing incidence of LM and LMM, particularly in men above 65 years of age (<a href="./references#CD010308-bbs2-0073" title="SwetterSM ,  BoldrickJC ,  JungSY ,  EgbertBM ,  HarvellJD . Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990‐2000. Journal of Investigative Dermatology2005;125(4):685‐91. [MEDLINE: 16185266] ">Swetter 2005</a>). Furthermore, in a recently published population‐based study held in the US, investigators report that the incidence of LM increased significantly among residents of Olmsted County, Minnesota, over a 37‐year period, with incidence being significantly higher among men than women and increasing with age (<a href="./references#CD010308-bbs2-0057" title="MirzoyevSA , KnudsonRM , ReedKB , HouJL , LohseCM , FrohmML , et al. Incidence of lentigo maligna in Olmsted County, Minnesota, 1970 to 2007. Journal of the American Academy of Dermatology2014;70(3):443‐8. [MEDLINE: 24373777] ">Mirzoyev 2014</a>). Across 21 years of incidence data for in situ and invasive lesions from the population‐based Queensland Cancer Registry in Australia, MIS increased by 10.4% per year among males and 8.4% per year among females. The incidence of invasive lesions also increased, but not as quickly (<a href="./references#CD010308-bbs2-0023" title="CooryM , BaadeP , AitkenJ , SmithersM , McLeodGR , RingI . Trends for in situ and invasive melanoma in Queensland, Australia, 1982‐2002. Cancer Causes &amp; Control2006;17(1):21‐7. [MEDLINE: 16411049] ">Coory 2006</a>). In a study evaluating incidence trends, age incidence relationships, and familial risks in invasive and in situ cutaneous melanoma, investigators in Sweden recorded a marked increase in incidence of MIS, particularly after 1985. Among MIS, lentigo maligna was the most common histogenetic type, almost three times more common than superficially spreading melanoma. The study obtained data from the Swedish Cancer Registry for the years 1961 to 1998 (<a href="./references#CD010308-bbs2-0036" title="HemminkiK , ZhangH , CzeneK . Incidence trends and familial risks in invasive and in situ cutaneous melanoma by sun‐exposed body sites. International Journal of Cancer2003;104(6):764‐71. [MEDLINE: 12640685] ">Hemminki 2003</a>). </p> <p>The real risk of progression from LM to LMM is not known; Cohen has widely reviewed this and estimated the risk to be "as high as 30% to 50% or as low as 5% based on epidemiologic data" (<a href="./references#CD010308-bbs2-0019" title="CohenLM . Lentigo maligna and lentigo maligna melanoma. Journal of American Academy of Dermatology1995;33(6):923‐36. [MEDLINE: 7490362] ">Cohen 1995</a>). Taking into account that observational, longitudinal, or prospective studies in people with LM are not feasible (since they would require no treatment), the precise lifetime risk of invasive melanoma in this group remains unknown. Investigators have estimated a lifetime risk essentially based on anecdotal experience. There is only one epidemiologic study that has aimed to establish the annual and lifetime risk of malignant transformation of LM (<a href="./references#CD010308-bbs2-0078" title="WeinstockMA , SoberAJ . The risk of progression of lentigo maligna to lentigo maligna melanoma. British Journal of Dermatology1987;116(3):303‐10. [MEDLINE: 3567069] ">Weinstock 1987</a>). Based on their records, the investigators reported that a person with LM at the age of 45 would have a 3.3% risk of LMM by the age of 75 and a lifetime risk of 4.7% (<a href="./references#CD010308-bbs2-0078" title="WeinstockMA , SoberAJ . The risk of progression of lentigo maligna to lentigo maligna melanoma. British Journal of Dermatology1987;116(3):303‐10. [MEDLINE: 3567069] ">Weinstock 1987</a>). Diagnosis of LM at the age of 65 was associated with a 1.2% risk of LMM by the age of 75 and a 2.2% lifetime risk (<a href="./references#CD010308-bbs2-0078" title="WeinstockMA , SoberAJ . The risk of progression of lentigo maligna to lentigo maligna melanoma. British Journal of Dermatology1987;116(3):303‐10. [MEDLINE: 3567069] ">Weinstock 1987</a>). The treatment of MIS, particularly the LM subtype, has been a controversial subject in the literature for over a decade. In the optimal scenario of being able to distinguish LM from LMM clinically, or being able to predict the risk of progression, close monitoring would be a reasonable alternative to treatment. However, since such a scenario is currently impossible, active treatment of LM is recommended (<a href="./references#CD010308-bbs2-0012" title="BichakjianCK ,  HalpernAC ,  JohnsonTM ,  Foote HoodA ,  GrichnikJM ,  SwetterSM ,  etal . Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. Journal of American Academy of Dermatology2011;65(5):1032‐47. [MEDLINE: 21868127] ">Bichakjian 2011</a>). These considerations have drawn special attention to the treatment of LM (<a href="./references#CD010308-bbs2-0027" title="EricksonC , MillerSJ . Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. International Journal of Dermatology2010;49(5):482‐91. [MEDLINE: 20534080] ">Erickson 2010</a>). </p> <section id="CD010308-sec-0018"> <h4 class="title">Clinical characteristics and diagnosis</h4> <p>Presentation of melanoma in situ may be quite subtle, and delayed recognition is common. Diagnosis is based on clinical, dermoscopic, and histological features. In terms of clinical presentation, it usually develops as an ill‐defined, darkly pigmented flat lesion, with irregular borders and a diameter larger than 0.7 cm. With regard to LM, the presence of widespread atypical melanocytes in the background of long‐standing sun damage are highly indicative of the disease (<a href="./references#CD010308-bbs2-0013" title="BrochezL , VerhaegheE , GrosshansE , HanekeE , PiérardG , RuiterD , et al. Inter‐observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. Journal of Pathology2002;196(4):459‐66. [MEDLINE: 11920743] ">Brochez 2002</a>; <a href="./references#CD010308-bbs2-0028" title="FarmerER , GoninR , HannaMP . Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Human Pathology1996;27(6):528‐31. [MEDLINE: 8666360] ">Farmer 1996</a>; <a href="./references#CD010308-bbs2-0043" title="KoehlerMJ ,  SpeicherM ,  Lange‐AsschenfeldtS ,  StockflethE ,  MetzS ,  ElsnerP ,  etal . Clinical application of multiphoton tomography in combination with confocal laser scanning microscopy for in vivo evaluation of skin diseases. Experimental Dermatology2011;20(7):589‐94. [MEDLINE: 21539618] ">Koehler 2011</a>; <a href="./references#CD010308-bbs2-0056" title="MegahedM ,  SchönM ,  SelimovicD ,  SchönMP . Reliability of diagnosis of melanoma in situ. Lancet2002;359(9321):1921‐2. [MEDLINE: 12057558] ">Megahed 2002</a>). However, differentiation from lentigo senilis, initial seborrhoeic keratosis, or pigmented actinic keratoses may be difficult (<a href="./references#CD010308-bbs2-0018" title="CognettaAB , StolzW , KatzB , TullosJ , GossainS . Dermatoscopy of lentigo maligna. Dermatologic Clinics2001;19(2):307‐18. [MEDLINE: 11556239] ">Cognetta 2001</a>). The four most important diagnostic features for LM or LMM on dermoscopy are "asymmetric pigmented follicular openings, dark rhomboidal structures, slate‐gray globules, and slate‐gray dots with a sensitivity of 89% and a specificity of 96%" (<a href="./references#CD010308-bbs2-0068" title="SchiffnerR , Schiffner‐RoheJ , VogtT , LandthalerM , WlotzkeU , CognettaAB , et al. Improvement of early recognition of lentigo maligna using dermatoscopy. Journal of the American Academy of Dermatology2000;42(1 Pt 1):25‐32. [MEDLINE: 10607316] ">Schiffner 2000</a>). </p> </section> </section> <section id="CD010308-sec-0019"> <h3 class="title" id="CD010308-sec-0019">Description of the intervention</h3> <p>Many interventions, including both surgical and non‐surgical therapeutic approaches, are used for the management of melanoma in situ. Surgical excision, including Mohs microsurgery, remains the gold standard therapeutic practice for people with melanoma in situ (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>; <a href="./references#CD010308-bbs2-0020" title="CohenLM , McCallMW , ZaxRH . Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow‐up study. Dermatologic Surgery1998;24(6):673‐7. [MEDLINE: 9648576] ">Cohen 1998</a>; <a href="./references#CD010308-bbs2-0024" title="DawnME , DawnAG , MillerSJ . Mohs surgery for the treatment of melanoma in situ: a review. Dermatologic Surgery2007;33(4):395‐402. [MEDLINE: 17430372] ">Dawn 2007</a>; <a href="./references#CD010308-bbs2-0046" title="KunishigeJH , BrodlandDG , ZitelliJA . Surgical margins for melanoma in situ. Journal of American Academy of Dermatology2012;66(3):438‐44. [MEDLINE: 22196979] ">Kunishige 2011</a>; <a href="./references#CD010308-bbs2-0053" title="MahoneyMH , JosephM , TempleCL . The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. Journal of Surgical Oncology2005;91(2):120‐5. [MEDLINE: 16028282] ">Mahoney 2005</a>; <a href="./references#CD010308-bbs2-0062" title="OsborneJE , HutchinsonPE . A follow‐up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. British Journal of Plastic Surgery2002;55(8):611‐5. [MEDLINE: 12550112] ">Osborne 2002</a>). </p> <section id="CD010308-sec-0020"> <h4 class="title">Surgical excision</h4> <section id="CD010308-sec-0021"> <h5 class="title">1. Regular excision with 5 mm margins</h5> <p>With regard to surgery, in 1992, the National Institutes of Health (NIH) consensus statement established surgical excision with 5 mm clinical margins as the standard treatment for melanoma in situ (<a href="./references#CD010308-bbs2-0061" title="National Institutes of Health. National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27‐29, 1992. American Journal of Dermatopathology1993;15(1):34‐43. [MEDLINE: 8434730] ">National Institutes of Health 1993</a>). However, taking into consideration cumulative evidence from multiple studies over recent years, the conclusion has been made that 5 mm margins are often insufficient to histologically clear the LM variant (<a href="./references#CD010308-bbs2-0060" title="National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (accessed 12 January 2011). ">National Comprehensive Cancer Network 2009</a>). The National Comprehensive Cancer Network's (NCCN) Guidelines of Care for Melanoma discussed the possible need for &gt; 5 mm margins in larger melanoma lesions of the lentigo maligna subtype (<a href="./references#CD010308-bbs2-0060" title="National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma. www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (accessed 12 January 2011). ">National Comprehensive Cancer Network 2009</a>); these guidelines stated that more extensive histological assessment of the margins may need to be considered in such cases. Thus, the conclusion from these guidelines and <a href="./references#CD010308-bbs2-0072" title="StevensonO , AhmedI . Lentigo maligna: prognosis and treatment options. American Journal of Clinical Dermatology2005;6(3):151‐64. [MEDLINE: 15943492] ">Stevenson 2005</a>, who showed that high rates of recurrence following standard excisional surgery, attributed to subclinical extension, is that a 5 mm surgical margin for excision of melanoma in situ is often insufficient for the LM subtype. </p> <p>In this context, given the need for extended margins, alternative techniques aiming to optimise margin control have been employed, including the square method, perimeter technique, 'slow Mohs', staged radial sections, staged "mapped" excisions, and Mohs micrographic surgery (MMS) (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). </p> </section> <section id="CD010308-sec-0022"> <h5 class="title">2. The square method</h5> <p>When using the square method, after drawing the original margins of the lesion, a new margin in the shape of a square or polygon is drawn at a distance of 5 mm from the original 1. Then, an additional square is drawn 2 to 3 mm around the latter polygon. This 2 to 3 mm slide of tissue around the lesion is excised, leaving behind a thin frame‐like defect that is simply sutured closed while waiting for the histopathologic report of the excised tissue. If the report is positive, another square frame is excised from the periphery, and the process is repeated until clear margins are obtained. At the final stage, the central part is excised, and the individual undergoes a reconstruction. </p> <p>"The key advantages of the 'square' method are that it allows the use of high‐quality permanent sections for total peripheral margin assessment and it avoids creating an open wound for the patient to care for while awaiting closure" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). One big disadvantage is that the individual must wait some time for pathology reports, possibly resulting in delayed complete excision. This important disadvantage of the square method has resulted in adaptations of the surgical technique (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>; <a href="./references#CD010308-bbs2-0039" title="JejurikarSS , BorschelGH , JohnsonTM , LoweL , BrownDL . Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plastic &amp; Reconstructive Surgery2007;120(5):1249‐55. [MEDLINE: 17898597] ">Jejurikar 2007</a>; <a href="./references#CD010308-bbs2-0040" title="JohnsonTM , HeadingtonJT , BakerSR , LoweL . Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. Journal of American Academy of Dermatology1997;37(5 Pt 1):758‐64. [MEDLINE: 9366823] ">Johnson 1997</a>). For example, the central part of the tumour is removed at first visit, without performing reconstruction (<a href="./references#CD010308-bbs2-0010" title="Agarwal‐AntalN , BowenGM , GerwelsJW . Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. Journal of American Academy of Dermatology2002;47(5):743‐8. [MEDLINE: 12399768] ">Agarwal‐Antal 2002</a>; <a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>; <a href="./references#CD010308-bbs2-0053" title="MahoneyMH , JosephM , TempleCL . The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. Journal of Surgical Oncology2005;91(2):120‐5. [MEDLINE: 16028282] ">Mahoney 2005</a>). This modification facilitates "staging prior to reconstruction but creates an open wound. Another common modification is the use of specific polygons [or curved lines] instead of a true square" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). "This allows the surgeon to match the surgical defect with the shape of the melanoma in situ as well as the surrounding cosmetic units and structures" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). Furthermore, straight lines are retained to facilitate histological processing. "Finally, another common modification is the use of 24‐hour rush permanent sections instead of routine processing" (<a href="./references#CD010308-bbs2-0014" title="BubJL , BergD , SleeA , OdlandPB . Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5‐year follow‐up. Archives of Dermatology2004;140(5):552‐8. [MEDLINE: 15148099] ">Bub 2004</a>). </p> </section> <section id="CD010308-sec-0023"> <h5 class="title">3. The "mapped" excision method</h5> <p>Hill and Gramp first described "mapped" excision in 1999 (<a href="./references#CD010308-bbs2-0038" title="HillDC , GrampAA . Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australasian Journal of Dermatology1999;40(1):25‐30. [MEDLINE: 10098285] ">Hill 1999</a>), as well as the 'radial processing' described by Bub, et al (<a href="./references#CD010308-bbs2-0014" title="BubJL , BergD , SleeA , OdlandPB . Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5‐year follow‐up. Archives of Dermatology2004;140(5):552‐8. [MEDLINE: 15148099] ">Bub 2004</a>). "While often included in review articles of melanoma in situ treatment for completeness, these forms of staged excisions do not employ en face [parallel to the surgical margins] histological processing and represent fundamentally different modalities than either the square method and its modifications or Mohs micrographic surgery" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). </p> </section> <section id="CD010308-sec-0024"> <h5 class="title">4. Mohs micrographic surgery</h5> <p>Mohs micrographic surgery (MMS) is a surgical and pathological procedure used to treat many cutaneous neoplasms (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>; <a href="./references#CD010308-bbs2-0059" title="MohsFE . Chemosurgery: a microscopically controlled method of cancer excision. Archives of Surgery1941;42(2):279‐95. ">Mohs 1941</a>). "Its design integrates the role of surgeon and pathologist and is unique in providing assessment of 100% of surgical margins intraoperatively, in contrast to a significantly lower percentage of assessed margins, typically 0.1% (<a href="./references#CD010308-bbs2-0080" title="ZitelliJA , BrownC , HanusaBH . Mohs micrographic surgery for the treatment of primary cutaneous melanoma. Journal of American Academy of Dermatology1997;37(2 Pt 1):236‐45. [MEDLINE: 9270510] ">Zitelli 1997</a>) to 5%, by standard specimen analysis" (<a href="./references#CD010308-bbs2-0070" title="ShrinerDL , McCoyDK , GoldbergDJ ,  WagnerRF . Mohs micrographic surgery. Journal of American Academy of Dermatology1998;39(1):79‐97. [MEDLINE: 9674401] ">Shriner 1998</a>). "Mohs micrographic surgery has the advantage of offering intraoperative margin control with assessment of 100% of margins, and it does not require a separate dermatopathologist to be available for rush specimen analysis" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). Even though the overall process may take several hours, achieving definitive excision and closure on the same day is a big advantage of MMS. A drawback of MMS is "the difficulty associated with adequately preparing frozen sections for [visualisation] of melanocytes, including the need for immunohistochemical stains" (<a href="./references#CD010308-bbs2-0017" title="ClarkGS , Pappas‐PolitisEC , CherpelisBS , MessinaJL , MöllerMG , CruseCW , et al. Surgical management of melanoma in situ on chronically sun damaged skin. Cancer Control2008;15(3):216‐24. [MEDLINE: 18596673] ">Clark 2008</a>). However, besides the progress in the field of excision techniques, the question concerning the initial margin size needed to clear a clinically ill‐defined tumour still remains (<a href="./references#CD010308-bbs2-0027" title="EricksonC , MillerSJ . Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. International Journal of Dermatology2010;49(5):482‐91. [MEDLINE: 20534080] ">Erickson 2010</a>). </p> </section> </section> <section id="CD010308-sec-0025"> <h4 class="title">Non‐surgical interventions</h4> <p>Localisation of lesions in cosmetically sensitive sites, such as the head and neck area, often raise serious difficulties for surgeons, who aim for complete clearance of the tumour, while seeking to minimise morbidity to the area. Similarly, the difficulty of obtaining wide excision margins in some body areas, together with the higher prevalence of lentigo maligna in the elderly (who may have contraindications to surgical procedures), has led to investigation of other less invasive treatment methods (<a href="./references#CD010308-bbs2-0027" title="EricksonC , MillerSJ . Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. International Journal of Dermatology2010;49(5):482‐91. [MEDLINE: 20534080] ">Erickson 2010</a>). In this context, radiotherapy (<a href="./references#CD010308-bbs2-0029" title="FarshadA ,  BurgG ,  PanizzonR ,  DummerR . A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X‐rays. British Journal of Dermatology2002;146(6):1042‐6. [MEDLINE: 12072074] ">Farshad 2002</a>; <a href="./references#CD010308-bbs2-0075" title="TsangRW , LiuFF , WellsW , PayneDG . Lentigo maligna of the head and neck: results of treatment by radiotherapy. Archives of Dermatology1994;130(8):1008‐12. [MEDLINE: 8053696] ">Tsang 1994</a>); cryosurgery (<a href="./references#CD010308-bbs2-0022" title="CollinsP , RogersS , GogginM , ManningW . Cryotherapy for lentigo maligna. Clinical &amp; Experimental Dermatology1991;16(6):433‐5. ">Collins 1991</a>); laser surgery (<a href="./references#CD010308-bbs2-0044" title="KoperaD . Treatment of lentigo maligna with the carbon dioxide laser. Archives of Dermatology1995;131(6):735‐6. [MEDLINE: 7778935] ">Kopera 1995</a>); and topical medication have been used with variable success, especially for individuals with large patches of LM, or those who are not otherwise good candidates for surgery (<a href="./references#CD010308-bbs2-0063" title="RajparSF , MarsdenJR . Imiquimod in the treatment of lentigo maligna. British Journal of Dermatology2006;155(4):653‐6. [MEDLINE: 16965411] ">Rajpar 2006</a>; <a href="./references#CD010308-bbs2-0064" title="RayCM , KlukM , GrinCM , Grant‐KelsJM . Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. International Journal of Dermatology2005;44(5):428‐34. [MEDLINE: 15869545] ">Ray 2005</a>; <a href="./references#CD010308-bbs2-0066" title="Rodriguez PrietoMA , Manchado LopezP , Ruiz GonzalezI , SuarezD . Treatment of lentigo maligna with azelaic acid. International Journal of Dermatology1993;32(5):363‐4. [MEDLINE: 8505164] ">Rodriguez Prieto 1993</a>; <a href="./references#CD010308-bbs2-0067" title="RyanRF , KrementzET , LitwinMS . A role for topical 5‐fluorouracil therapy in melanoma. Journal of Surgical Oncology1988;38(4):250‐6. [MEDLINE: 3045424] ">Ryan 1988</a>). Apart from their use as primary treatments, non‐surgical techniques can contribute as adjuvant therapies after surgical excision, in order to minimise recurrence, or after incomplete excision to further enhance the therapeutic response. A recent trend also includes application of non‐ablative treatments as neoadjuvant therapies, before surgical treatment of large lesions or difficult sites, in order to achieve smaller surgical excisions (<a href="./references#CD010308-bbs2-0035" title="GuptaAK , ChermanAM , TyringSK . Viral and nonviral uses of imiquimod: a review. Journal of Cutaneous Medicine &amp; Surgery2004;8(5):338‐52. [MEDLINE: 15868314] ">Gupta 2004</a>), although there is concern over the potential for creating non‐contiguous tumour islands. </p> </section> <section id="CD010308-sec-0026"> <h4 class="title">Lasers</h4> <p>Carbon dioxide laser ablation, Q‐switched neodymium‐doped yttrium aluminium garnet (QS Nd:YAG), and alexandrite lasers have all been used in the treatment of LM in those elderly people who may be unsuitable for surgery (<a href="./references#CD010308-bbs2-0049" title="LeeH , SowerbyLJ , TempleCL , YuE , MooreCC . Carbon dioxide laser treatment for lentigo maligna: a retrospective review comparing 3 different treatment modalities. Archives of Facial Plastic Surgery2011;13(6):398‐403. [MEDLINE: 22106185] ">Lee 2011</a>; <a href="./references#CD010308-bbs2-0052" title="MadanV , AugustPJ . Lentigo maligna‐outcomes of treatment with Q‐switched Nd:YAG and alexandrite lasers. Dermatological Surgery2009;35(4):607‐11. [MEDLINE: 19309345] ">Madan 2009</a>). </p> </section> <section id="CD010308-sec-0027"> <h4 class="title">Curettage and electrodesiccation</h4> <p>Curettage and electrosurgery have been used for the treatment of lentigo maligna (<a href="./references#CD010308-bbs2-0021" title="ColemanWP ,  DavisRS ,  ReedRJ ,  KrementzET . Treatment of lentigo maligna and lentigo maligna melanoma. Journal of Dermatologic Surgery &amp; Oncology1980;6(6):476‐9. [MEDLINE: 7391322] ">Coleman 1980</a>). Usually, a looped metal instrument (curettage) is used to 'scrape' the lesion's surface and remove part or the whole of the lesion, and an electric current (electrosurgery) is applied to cauterise and destroy an area of the lesion. Recurrences have been observed. The main drawback of this technique is the lack of histological analysis. It has also been reported that atypical melanocytes in the hair follicle are not likely to be destroyed using this technique (<a href="./references#CD010308-bbs2-0034" title="GasparZS ,  DawberRP . Treatment of lentigo maligna. Australasian Journal of Dermatology1997;38(1):1‐8. [MEDLINE: 9046644] ">Gaspar 1997</a>). </p> </section> <section id="CD010308-sec-0028"> <h4 class="title">Radiation therapy</h4> <p>"Radiation therapy is [a] non‐invasive treatment modality that has been used as a primary treatment for lentigo maligna. It is appealing in elderly patients who may be poor surgical candidates and in patients with large lentigo malignas on the face that would require a large surgical excision" (<a href="./references#CD010308-bbs2-0033" title="GarbeC , HauschildA , VolkenandtM , SchadendorfD , StolzW , ReinholdU , et al. Evidence and interdisciplinary consensus‐based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research2008;18(1):61‐7. [MEDLINE: 18227710] ">Garbe 2008</a>). Cure rates for lentigo maligna achieved with radiotherapy, with either Grenz rays or soft X‐rays using the Miescher technique, range from 86% to 95% (<a href="./references#CD010308-bbs2-0029" title="FarshadA ,  BurgG ,  PanizzonR ,  DummerR . A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X‐rays. British Journal of Dermatology2002;146(6):1042‐6. [MEDLINE: 12072074] ">Farshad 2002</a>; <a href="./references#CD010308-bbs2-0069" title="Schmid‐WendtnerMH , BrunnerB , KonzB , KaudewitzP ,  WendtnerCM ,  PeterRU , et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. Journal of American Academy of Dermatology2000;43(3):477‐82. [MEDLINE: 10954659] ">Schmid‐Wendtner 2000</a>; <a href="./references#CD010308-bbs2-0075" title="TsangRW , LiuFF , WellsW , PayneDG . Lentigo maligna of the head and neck: results of treatment by radiotherapy. Archives of Dermatology1994;130(8):1008‐12. [MEDLINE: 8053696] ">Tsang 1994</a>). </p> <p>The German Cancer Society suggested "radiotherapy as a potential second line treatment for lentigo maligna in their 2008 guidelines (<a href="./references#CD010308-bbs2-0033" title="GarbeC , HauschildA , VolkenandtM , SchadendorfD , StolzW , ReinholdU , et al. Evidence and interdisciplinary consensus‐based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research2008;18(1):61‐7. [MEDLINE: 18227710] ">Garbe 2008</a>). The [therapeutic] protocol reported in these guidelines includes Grenz ray therapy (12 kV) for LM (100 to 120 Gy; 10 Gy twice weekly for 5 to 6 weeks). However, the German consensus statement did conclude that radiation therapy for the primary treatment of melanoma is indicated only in those cases in which surgery is impossible or not reasonable". </p> </section> <section id="CD010308-sec-0029"> <h4 class="title">Cryosurgery</h4> <p>Cryosurgery has been proposed as an alternative to surgical excision for lentigo maligna (<a href="./references#CD010308-bbs2-0030" title="FieldLM . Cryosurgery for lentigo maligna. Journal of American Academy of Dermatology1995;32(4):686‐7. [MEDLINE: 7896972] ">Field 1995</a>). It is recommended in people for whom surgery is not appropriate. The cryosurgery technique varies. Kufiick and Gage suggested "aggressive treatment [using] double freeze‐thaw cycles with a 1 cm margin and temperatures of ‐40 to ‐50°C at the base of the lesion" (<a href="./references#CD010308-bbs2-0045" title="KuflikEG , GageAA . Cryosurgery for lentigo maligna. Journal of American Academy of Dermatology1994;31(1):75‐8. [MEDLINE: 8021376] ">Kuflik 1994</a>). A significant drawback in cryosurgery is the lack of a histological evaluation of the destroyed specimen. As a result of the latter, no assessment of microscopic foci of lentigo maligna melanoma or identification of aggressive melanoma subtypes can be made. On the same basis, it does not give any clue to the prognostic outcome based on histological grade in case of an invasive tumour. </p> </section> <section id="CD010308-sec-0030"> <h4 class="title">Imiquimod</h4> <p>Imiquimod belongs to the synthetic imidazoquinoline amine family. It is used as a topical immune‐response modifier, and is officially approved for the treatment of superficial basal cell carcinoma, actinic keratoses, and external genital warts. Because of the antitumour effect of imiquimod, it has been used for many other neoplasias, including melanoma in situ (<a href="./references#CD010308-bbs2-0064" title="RayCM , KlukM , GrinCM , Grant‐KelsJM . Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. International Journal of Dermatology2005;44(5):428‐34. [MEDLINE: 15869545] ">Ray 2005</a>). However, success rates are variable, and recurrence with progression to invasive melanoma has been reported (<a href="./references#CD010308-bbs2-0079" title="WoodmanseeCS , McCallMW . Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatologic Surgery2009;35(8):1286‐9. [MEDLINE: 19438661] ">Woodmansee 2009</a>). </p> </section> <section id="CD010308-sec-0031"> <h4 class="title">Azelaic acid</h4> <p>Azelaic acid has been successfully used in the treatment of lentigo maligna melanoma (<a href="./references#CD010308-bbs2-0066" title="Rodriguez PrietoMA , Manchado LopezP , Ruiz GonzalezI , SuarezD . Treatment of lentigo maligna with azelaic acid. International Journal of Dermatology1993;32(5):363‐4. [MEDLINE: 8505164] ">Rodriguez Prieto 1993</a>; <a href="./references#CD010308-bbs2-0076" title="VereeckenP , HeenenM . Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. International Journal of Clinical Practice2002;56(1):68‐9. [MEDLINE: 11831841] ">Vereecken 2002</a>). The precise mechanism of action responsible for this beneficial effect remains obscure. Numerous investigators have used azelaic acid 20% in a cream, or 15% to 55% in ointment, for a number of months to over a year for the treatment of lentigo maligna (<a href="./references#CD010308-bbs2-0066" title="Rodriguez PrietoMA , Manchado LopezP , Ruiz GonzalezI , SuarezD . Treatment of lentigo maligna with azelaic acid. International Journal of Dermatology1993;32(5):363‐4. [MEDLINE: 8505164] ">Rodriguez Prieto 1993</a>; <a href="./references#CD010308-bbs2-0076" title="VereeckenP , HeenenM . Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. International Journal of Clinical Practice2002;56(1):68‐9. [MEDLINE: 11831841] ">Vereecken 2002</a>). However, the results have varied between studies. </p> </section> <section id="CD010308-sec-0032"> <h4 class="title">5‐fluorouracil</h4> <p>Topical chemotherapy of lentigo maligna of the face with 5‐fluorouracil 5% cream has been used (<a href="./references#CD010308-bbs2-0051" title="LitwinMS ,  KrementzET ,  MansellPW ,  ReedRJ . Topical chemotherapy of lentigo maligna with 5‐fluorouracil. Cancer1975;35(3):721‐33. [MEDLINE: 1111940] ">Litwin 1975</a>). </p> </section> </section> <section id="CD010308-sec-0033"> <h3 class="title" id="CD010308-sec-0033">How the intervention might work</h3> <p>Of the main interventions mentioned above, cryosurgery acts through the direct 'killing' of the melanocytes at temperatures of ‐ 4 to ‐7 °C (<a href="./references#CD010308-bbs2-0032" title="GageAA , MeenaghanMA , NatiellaJR , GreeneGW . Sensitivity of pigmented mucosa and skin to freezing injury. Cryobiology1979;16(4):348‐61. [PUBMED: 487851] ">Gage 1979</a>), and imiquimod activates the innate immune response by binding to receptors on neutrophils, macrophages, and dendritic cells. This leads to synthesis and release of cytokines, including tumour necrosis factor‐α (<a href="./references#CD010308-bbs2-0041" title="KangHY , ParkTJ , JinSH . Imiquimod, a Toll‐like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. Journal of Investigative Dermatology2009;129(1):243‐6. [MEDLINE: 18596825] ">Kang 2009</a>), which has been shown to have significant antitumour effects. There have been several studies of the mechanism of action of azelaic acid (<a href="./references#CD010308-bbs2-0009" title="Addo‐BoaduK , WojtaJ , ChristG , HufnaglP , PehambergerH , BinderBR . Azelaic acid decreases the fibrinolytic potential of cultured human melanoma cells in vitro. Cancer Letters1996;103(2):125‐9. [MEDLINE: 8635147] ">Addo‐Boadu 1996</a>; <a href="./references#CD010308-bbs2-0050" title="LeiblH , StinglG , PehambergerH , KorschanH , KonradK , WolffK . Inhibition of DNA synthesis of melanoma cells by azelaic acid. Journal of Investigative Dermatology1985;85(5):417‐22. [MEDLINE: 4056455] ">Leibl 1985</a>), but "inhibition of DNA synthesis is one of the mechanisms by which azelaic acid prevents growth and proliferation of abnormal melanocytes" (<a href="./references#CD010308-bbs2-0050" title="LeiblH , StinglG , PehambergerH , KorschanH , KonradK , WolffK . Inhibition of DNA synthesis of melanoma cells by azelaic acid. Journal of Investigative Dermatology1985;85(5):417‐22. [MEDLINE: 4056455] ">Leibl 1985</a>). Finally, 5‐fluorouracil inhibits a cell's ability to synthesise DNA by inducing cell cycle arrest and apoptosis (programmed cell death) (<a href="./references#CD010308-bbs2-0025" title="DesaiT ,  ChenCL ,  DesaiA ,  KirbyW . Basic pharmacology of topical imiquimod, 5‐fluorouracil, and diclofenac for the dermatologic surgeon. Dermatological Surgery2012;38(1):97‐103. [PUBMED: 22092926] ">Desai 2012</a>). </p> </section> <section id="CD010308-sec-0034"> <h3 class="title" id="CD010308-sec-0034">Why it is important to do this review</h3> <p>We think it is very important to systematically evaluate all of the available surgical and non‐surgical therapeutic options for the treatment of melanoma in situ, since it predisposes to the deadliest type of skin cancer (i.e., invasive melanoma), and its incidence is growing rapidly. </p> <p>We published the plans for this review as a protocol 'Interventions for melanoma in situ, including lentigo maligna' (<a href="./references#CD010308-bbs2-0081" title="ApallaZ , TzellosT , KyrgidisA , MocellinS , ChanAW , Haque HussainS , PilatiP . Interventions for melanoma in situ, including lentigo maligna. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD010308] ">Apalla 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010308-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010308-sec-0035"></div> <p>To assess the effects of all available interventions, surgical and non‐surgical, for the treatment of melanoma in situ, including LM. </p> <p>We also aimed to assess efficacy, harms, and tolerability of postoperative adjuvant therapies after surgical treatment, as well as the efficacy, harms, and tolerability of non‐surgical interventions preoperatively (neoadjuvant therapies), in order to facilitate surgical removal. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010308-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010308-sec-0036"></div> <section id="CD010308-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010308-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials of any design of the management of melanoma in situ, including LM, that compared any intervention to placebo or active treatment. </p> </section> <section id="CD010308-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included individuals, irrespective of age and sex, diagnosed with melanoma in situ, including LM, based on histological examination by healthcare practitioners. </p> </section> <section id="CD010308-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included surgical (regular excision with 5 mm margins, Mohs surgery, staged excision, etc.) and non‐surgical (imiquimod, lasers, cryosurgery, etc.) treatments, alone or in combination with other treatments, for the management of melanoma in situ, including LM. </p> </section> <section id="CD010308-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>The outcome measures of interest were those that estimated clinical efficacy, harms, or tolerability in a reliable and valid way. </p> <section id="CD010308-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010308-list-0001"> <li> <p>Histological or clinical complete response rate.</p> </li> <li> <p>Total number of acute and short‐term (up to one year) treatment‐related adverse events.</p> </li> </ol> </p> </section> <section id="CD010308-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010308-list-0002"> <li> <p>Clinical or histological local recurrence rate.</p> </li> <li> <p>Time to complete histological or clinical clearance (for surgical and non‐surgical treatments). </p> </li> <li> <p>Time to histological or clinical local recurrence.</p> </li> <li> <p>Incidence of distal metastases.</p> </li> <li> <p>Progression to invasive melanoma.</p> </li> <li> <p>Short‐, medium‐, and long‐term participant satisfaction.</p> </li> <li> <p>Treatment‐related quality of life.</p> </li> <li> <p>Discontinuation of treatment rate because of harms.</p> </li> <li> <p>Inflammatory response.</p> </li> </ol> </p> <section id="CD010308-sec-0044"> <h6 class="title">Main outcomes for the 'Summary of findings' table</h6> <p>We provided data in the <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a> for the primary and secondary outcomes. </p> </section> <section id="CD010308-sec-0045"> <h6 class="title">Timing of outcomes</h6> <p>We summarised and pooled outcomes according to the following time schedule: up to one year, between one to five years, and longer than five years from treatment initiation, for the short‐, medium‐, and long‐term outcomes, respectively. We classified treatment‐related harms as 'acute' if they arose during treatment or within two weeks of treatment completion. Analysis of participant satisfaction took place at the same time points. </p> </section> <section id="CD010308-sec-0046"> <h6 class="title">Economic data</h6> <p>We did not consider economic factors in this review.</p> </section> </section> </section> </section> <section id="CD010308-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD010308-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 26 November 2014:</p> <p> <ul id="CD010308-list-0003"> <li> <p>the Cochrane Skin Group Specialised Register using the search strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-01" target="_blank">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (2014, Issue 10) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-03" target="_blank">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-04" target="_blank">Appendix 4</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-05" target="_blank">Appendix 5</a>. </p> </li> </ul> </p> <p>We searched the following databases up to 30 November 2014 using the strategy in <a href="./appendices#CD010308-sec-0122">Appendix 6</a>: </p> <p> <ul id="CD010308-list-0004"> <li> <p>African Index Medicus (<a href="http://indexmedicus.afro.who.int" target="_blank">indexmedicus.afro.who.int</a>, from inception); </p> </li> <li> <p>IndMED of India (<a href="http://indmed.nic.in" target="_blank">indmed.nic.in</a>, from inception); and </p> </li> <li> <p>Index Medicus for the South‐East Asia Region (IMSEAR) (from inception).</p> </li> </ul> </p> <section id="CD010308-sec-0049"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers up to 30 November 2014 using the following search string: ["lentigo maligna" OR "lentigo maligna melanoma" OR "Hutchinson Melanotic Freckle" OR "melanoma in‐situ" OR "melanoma in situ" OR "melanoma‐in‐situ" OR (melanoma NEAR in‐situ)]. </p> <p> <ul id="CD010308-list-0005"> <li> <p>The metaRegister of Controlled Trials (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>). </p> </li> <li> <p>The South African National Clinical Trials Register (<a href="http://www.sanctr.gov.za" target="_blank">www.sanctr.gov.za</a>). </p> </li> </ul> </p> </section> </section> <section id="CD010308-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD010308-sec-0051"> <h5 class="title">References from published studies</h5> <p>We checked the bibliographies of included and excluded studies for further references to relevant trials. </p> </section> <section id="CD010308-sec-0052"> <h5 class="title">Unpublished literature</h5> <p>We tried to identify further relevant trials by sharing our lists of included and excluded studies with industry contacts and other experts in the field of melanoma. We asked if they knew of any further relevant trials on melanoma in situ and also whether they were aware of melanoma trials where a subset of participants had melanoma in situ. </p> </section> <section id="CD010308-sec-0053"> <h5 class="title">Conference proceedings</h5> <p>In order to identify eligible studies from conference proceedings, we checked the Conference Proceedings Citation Index, accessed via Web of Science™ Core Collection, and Cochrane conference proceedings up to 17 February 2014. We scanned the abstracts of the following major dermatology and oncology conference proceedings, where they were not already recorded in the Cochrane Skin Group Specialised Register: </p> <p> <ul id="CD010308-list-0006"> <li> <p>American Academy of Dermatology (2008/2009);</p> </li> <li> <p>European Academy of Dermatology and Venereology (EADV) (from 2006);</p> </li> <li> <p>European Academy of Dermatology and Venereology Spring Symposium (from 2006);</p> </li> <li> <p>Society for Investigative Dermatology (SID) (2007/2008/2009); and</p> </li> <li> <p>World Congress of Dermatology (from 2002).</p> </li> </ul> </p> </section> <section id="CD010308-sec-0054"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target interventions. We considered adverse effects and side‐effects described in included studies only. </p> </section> </section> </section> <section id="CD010308-sec-0055"> <h3 class="title" id="CD010308-sec-0055">Data collection and analysis</h3> <p>Some parts of the methods section of this review uses text that was originally published in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010308-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <section id="CD010308-sec-0056"> <h4 class="title">Selection of studies</h4> <p>Two authors (TT and AK) independently examined titles and abstracts of each reference identified in the search results. We checked them independently and resolved any differences related to what we should include or exclude by referring to a third author (SM or AWC). We obtained the full text of all articles that either met the inclusion criteria or for which reading the full text was necessary to decide on their eligibility. </p> </section> <section id="CD010308-sec-0057"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TT and AK) independently extracted the data on to a standard data extraction form, which we had modified for our review. Although we were blinded to each other's data extraction, we were not blinded to the journal of publication or to the trial author names. We resolved differences by discussion with a third author (SM or AWC). We extracted data according to Table 7.3.a 'Checklist of items to consider in data collection or data extraction' in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010308-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Two review authors (TT and AK) entered data into the '<a href="./references#CD010308-sec-0133" title="">Characteristics of included studies</a>' table in <a href="./references#CD010308-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> (RevMan). </p> <p>Briefly, we tried to extract the following data: general study information, trial methodology, key variables characterising the participants, key variables characterising the lesion, key variables characterising the intervention, outcomes, and results. </p> <p> <ul id="CD010308-list-0007"> <li> <p>General study information</p> </li> </ul> <ul class="plain" id="CD010308-list-0008"> <li> <ul id="CD010308-list-0009"> <li> <p>Author</p> </li> <li> <p>Publication status (full report/abstract/unpublished data)</p> </li> <li> <p>Year of trial initiation</p> </li> <li> <p>Publication date</p> </li> <li> <p>Source of study/funding</p> </li> <li> <p>Setting (place trial was conducted)</p> </li> <li> <p>Dual publication</p> </li> <li> <p>Language of original publication</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0010"> <li> <p>Trial methodology</p> </li> </ul> <ul class="plain" id="CD010308-list-0011"> <li> <ul id="CD010308-list-0012"> <li> <p>Design</p> </li> <li> <p>Type of trial</p> </li> <li> <p>Study duration</p> </li> <li> <p>Sequence generation</p> </li> <li> <p>Allocation sequence concealment</p> </li> <li> <p>Participant/provider and outcome assessor blinding</p> </li> <li> <p>Number of participants allocated to each treatment group</p> </li> <li> <p>Number of dropouts and reasons for dropouts</p> </li> <li> <p>Intention‐to‐treat analysis or not</p> </li> <li> <p>Method/duration of follow‐up period</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0013"> <li> <p>Key variables characterising the participants</p> </li> </ul> <ul class="plain" id="CD010308-list-0014"> <li> <ul id="CD010308-list-0015"> <li> <p>Age</p> </li> <li> <p>Sex</p> </li> <li> <p>Nationality</p> </li> <li> <p>Duration of lesion</p> </li> <li> <p>Comparability of study groups at entry</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Recruitment method</p> </li> <li> <p>Number of participants enrolled</p> </li> <li> <p>Previous treatment</p> </li> <li> <p>Immunocompetent or not (e.g., B‐cell lymphoma, transplantation)</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0016"> <li> <p>Key variables characterising the lesion</p> </li> </ul> <ul class="plain" id="CD010308-list-0017"> <li> <ul id="CD010308-list-0018"> <li> <p>Type of lesion</p> </li> <li> <p>Site</p> </li> <li> <p>Size</p> </li> <li> <p>How the diagnosis was established (histological criteria used)</p> </li> <li> <p>Melanotic or amelanotic</p> </li> <li> <p>One or multiple lesions</p> </li> <li> <p>Type of biopsy used (punch, excisional, incisional)</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0019"> <li> <p>Key variables characterising the intervention</p> </li> </ul> <ul class="plain" id="CD010308-list-0020"> <li> <ul id="CD010308-list-0021"> <li> <p>Type of intervention</p> <ul id="CD010308-list-0022"> <li> <p>For surgical intervention: type of surgical procedure (standard excision, Mohs surgery, etc.), size of postoperative surgical defect, number of stages required; type of reconstruction </p> </li> <li> <p>For topical treatment: duration, mode of application, time of application, if occlusion or not, when treatment stopped (e.g., weeping erosion appeared), if concomitant treatment (cryotherapy) applied, if inflammatory response appeared </p> </li> </ul> </li> <li> <p>Use of concomitant therapy</p> </li> <li> <p>Evidence of compliance monitoring</p> </li> <li> <p>For cryotherapy: mode of application, description of freeze‐thaw cycles</p> </li> <li> <p>For laser: type of laser (Argon, Q‐switched ruby, QS Nd:YAG, alexandrite laser), method of application </p> </li> </ul> </li> </ul> <ul id="CD010308-list-0023"> <li> <p>Outcomes</p> </li> </ul> <ul class="plain" id="CD010308-list-0024"> <li> <ul id="CD010308-list-0025"> <li> <p>Outcomes used and time points</p> </li> <li> <p>Diagnostic criteria used and outcome definition</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0026"> <li> <p>Results</p> </li> </ul> <ul class="plain" id="CD010308-list-0027"> <li> <ul id="CD010308-list-0028"> <li> <p>Lost to follow up</p> </li> <li> <p>Summary data for each intervention group</p> </li> <li> <p>Mean and standard deviation for continuous data</p> </li> <li> <p>The number of participants with the outcome event and the denominator for categorical outcomes </p> </li> <li> <p>Estimate of effect with confidence intervals</p> </li> <li> <p>Subgroup analyses (specific subsets of participants)</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010308-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TT and AK) independently assessed the quality and the risk of bias of the eligible study. We resolved any disagreement by discussion and arbitration or by consensus with a third author (SM or AWC). Where necessary, we contacted trial authors for clarification. Quality evaluation and assessment of the risk of bias included evaluation of the following components for the included trial, using the 'Risk of bias' tool suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010308-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): </p> <p>(a) method of generation of the randomisation sequence;<br/> (b) method of allocation concealment ‐ we considered this as adequate if the assignment could not be foreseen by either participants or investigator;<br/> (c) blinding (who was blinded/not blinded) in order to assess performance bias ‐ we considered this adequate if participants, investigators, and assessors were blinded as to who received the intervention and who received the placebo/other treatment;<br/> (d) loss to follow up (in each arm); and<br/> (e) whether participants were analysed in the groups to which they were originally randomised (intention‐to‐treat). </p> <p>Furthermore, we assessed if baseline comparisons of groups regarding important confounding variables were made, in order to assess selection bias. </p> <p>We also carefully assessed the following:</p> <p> <ol id="CD010308-list-0029"> <li> <p>if method and duration of follow‐up period were adequate;</p> </li> <li> <p>definition of partial clearance;</p> </li> <li> <p>definition of complete clinical clearance; and</p> </li> <li> <p>definition of clinical local recurrence.</p> </li> </ol> </p> </section> <section id="CD010308-sec-0059"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous outcomes as risk ratios (RR), with 95% confidence intervals (CIs). We expressed continuous outcomes as mean differences (MD), with 95% CIs. We expressed continuous outcomes that were measured with different methodologies across studies as standardised mean differences (SMD), with 95% CIs. </p> </section> <section id="CD010308-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>If we had found cross‐over trials, we would have only considered data from the first period. We would have pooled data from the first period of cross‐over trials with data from parallel‐group studies. If multiple‐treatment group trials were eligible, we would have combined groups to create a single pair‐wise comparison following recommendations from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 16) (<a href="./references#CD010308-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If there were no relevant intervention groups that we could combine, we would have considered multiple‐treatment meta‐analyses. For intraindividual studies, we would have considered each body part as the unit of analysis. </p> </section> <section id="CD010308-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data in our included trial as if the analysis was undertaken using intention‐to‐treat. If the analysis of the trial data had been performed using per‐protocol analysis or it was clear that the number of participants analysed for the outcome were not the same as those randomised, thereby excluding intention‐to‐treat analysis, we would have contacted the original investigators to obtain missing data. If contact with the author was not fruitful, we would have used imputation techniques, if possible, based on assumptions ‐ the validity of which we would have assessed through sensitivity analyses. If the results of the sensitivity analysis were suggestive of bias, we would have performed available‐case analysis and reported (with the intention of comparing the two) the results of both methods. </p> </section> <section id="CD010308-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We would have assessed statistical heterogeneity using I² statistic. If I² statistic for the primary outcomes was greater than 50%, we would have ascertained that significant heterogeneity was present. Thus, we would have explored this using prespecified subgroup analyses taking into consideration reasons, such as differences in participants and treatment factors. </p> </section> <section id="CD010308-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had included more than 10 studies in the meta‐analysis, we had planned to use funnel plots to visually analyse the existence of publication bias. Additionally, we aimed to perform the Egger's test (<a href="./references#CD010308-bbs2-0026" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>) to formally assess the symmetry of funnel plots. </p> </section> <section id="CD010308-sec-0064"> <h4 class="title">Data synthesis</h4> <p>If there had been sufficient studies and if no evidence of heterogeneity between eligible studies existed (I² statistic &lt; 25%), we aimed to synthesise data using fixed‐effect models. Otherwise, we would have used random‐effects models. For dichotomous outcomes, we would have pooled risk ratios (RR) and corresponding 95% confidence intervals (CI) from individual studies. For continuous outcomes, we would have pooled the mean difference (MD) and corresponding 95% CIs from individual studies. </p> </section> <section id="CD010308-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Following assessment of heterogeneity, we aimed to perform exploratory subgroup analysis to identify factors that could explain efficacy, safety, or tolerability, or that could explain heterogeneity. </p> <p>The following were possible subgroups.</p> <p> <ul id="CD010308-list-0030"> <li> <p>Study factors</p> </li> </ul> <ul class="plain" id="CD010308-list-0031"> <li> <ul id="CD010308-list-0032"> <li> <p>Design</p> </li> <li> <p>Risk of bias of included studies</p> </li> <li> <p>Length of follow up</p> </li> </ul> </li> </ul> <ul id="CD010308-list-0033"> <li> <p>Treatment factors</p> </li> </ul> <ul class="plain" id="CD010308-list-0034"> <li> <ul id="CD010308-list-0035"> <li> <p>Length of treatment</p> </li> <li> <p>Treatment schedule</p> </li> </ul> </li> </ul> </p> <p>The number of studies included was insufficient, and we were not able to consider these factors. </p> </section> <section id="CD010308-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform sensitivity analyses to examine the effects of excluding study subgroups or certain studies of low methodological quality. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010308-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010308-sec-0067"></div> <section id="CD010308-sec-0068"> <h3 class="title">Description of studies</h3> <p>We report the characteristics of studies in the '<a href="./references#CD010308-sec-0133" title="">Characteristics of included studies</a>' table, '<a href="./references#CD010308-sec-0134" title="">Characteristics of excluded studies</a>' tables, and '<a href="./references#CD010308-sec-0136" title="">Characteristics of ongoing studies</a>' table. A summary of findings is presented in <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD010308-sec-0069"> <h4 class="title">Results of the search</h4> <p><a href="#CD010308-fig-0001">Figure 1</a> depicts a study flow diagram. In summary, we identified 809 records in total. We removed 27 duplicates, leaving 782 records for screening. Following exclusion of 774 records on the basis of title and abstract, we screened 8 for eligibility and inclusion with full text assessment. From these 8 studies, we excluded 4 and provided reasons in the '<a href="./references#CD010308-sec-0134" title="">Characteristics of excluded studies</a>' tables; we cannot currently make a decision about 2 studies, so they are detailed in the '<a href="./references#CD010308-sec-0135" title="">Characteristics of studies awaiting classification</a>' tables; 1 other study is ongoing in the active recruitment phase and fulfilled the criteria for inclusion (<a href="./references#CD010308-bbs2-0008" title="NCT01720407 . Relevance of Imiquimod as Neo‐adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc). clinicaltrials.gov/show/NCT01720407 (accessed 20 March 2014). ">NCT01720407</a>). One study, <a href="./references#CD010308-bbs2-0001" title="HydeMA , HadleyML , Tristani‐FirouziP , GoldgarD , BowenGM . A Randomized Trial of the Off‐Label Use of Imiquimod, 5%, Cream with vs without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions. Archives of Dermatology2012;148(5):592‐6. [MEDLINE: 22431716] ">Hyde 2012</a>, was completed with results and fulfilled criteria for inclusion. </p> <div class="figure" id="CD010308-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD010308-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD010308-sec-0070"> <h4 class="title">Included studies</h4> <p>Our search identified only one study eligible for inclusion, <a href="./references#CD010308-bbs2-0001" title="HydeMA , HadleyML , Tristani‐FirouziP , GoldgarD , BowenGM . A Randomized Trial of the Off‐Label Use of Imiquimod, 5%, Cream with vs without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions. Archives of Dermatology2012;148(5):592‐6. [MEDLINE: 22431716] ">Hyde 2012</a>, with 90 participants. </p> <section id="CD010308-sec-0071"> <h5 class="title">Design</h5> <p>This was a randomised, single centre, open label, parallel group, two‐arm, controlled trial. </p> </section> <section id="CD010308-sec-0072"> <h5 class="title">Participants</h5> <p>Ninety participants (24 women, 66 men), who had 91 lentigo maligna (LM) lesions with histologically proven LM, participated and underwent initial shave excision of any visible tumour. The mean age of the participants was 68.2 years (age range: 35 to 92). </p> </section> <section id="CD010308-sec-0073"> <h5 class="title">Interventions</h5> <p>Forty‐four participants (13 women, 31 men), with 44 LM lesions, were treated with imiquimod 5% cream 5 days/week (from Monday to Friday) plus tazarotene 0.1% gel 2 days/week (Saturday and Sunday) for 3 months, and 46 participants (11 women, 35 men), with 47 LM lesions, were treated with imiquimod 5% cream 5 days/week (from Monday to Friday) for 3 months. </p> <p>Participants in all groups treated an area extending 1 inch (2.54 cm) beyond the outlined tumour margins. Two months after cessation of topical treatment, the initial tumour footprint was excised using 2 mm margins via a staged excision with radial frozen sections and melan‐A immunostaining to confirm negative margins. </p> </section> <section id="CD010308-sec-0074"> <h5 class="title">Outcomes</h5> <p>The primary outcome of the study was histological complete response (histological complete clearance) at month five after the initiation of treatment. The secondary outcomes included local recurrence rate, progression to invasive melanoma, discontinuation of treatment because of harms, and overall inflammation score (inflammatory response). </p> </section> <section id="CD010308-sec-0075"> <h5 class="title">Setting</h5> <p>Only one centre in a university‐setting participated in this study. The study had no funding support. Contact with the corresponding author of the included study (Dr Mark Hyde) was successful, and he provided access to primary study data and replied, when possible, to all of our inquiries. </p> </section> </section> <section id="CD010308-sec-0076"> <h4 class="title">Excluded studies</h4> <p>We excluded four studies and provide reasons for their exclusion in the '<a href="./references#CD010308-sec-0134" title="">Characteristics of excluded studies</a>' tables. After evaluation of the full text, we found that two did not include people with melanoma in situ (<a href="./references#CD010308-bbs2-0003" title="KhayatD , RixeO , MartinG , SoubraneC , BanzetM , BazexJA , et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1‐mm thick): Long‐term results of a large European multicentric phase III study. Cancer2003;97(8):1941‐6. [EMBASE: 2003143819] ">Khayat 2003</a>; <a href="./references#CD010308-bbs2-0004" title="KimKB , EtonO , DavisDW , FrazierML , McConkeyDJ , DiwanAH , et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. British Journal of Cancer2008;99(5):734‐40. [EMBASE: 2008407391] ">Kim 2008</a>), and two did not compare treatments (<a href="./references#CD010308-bbs2-0002" title="ChagparRB , RossMI , ReintgenDS , EdwardsMJ , ScogginsCR , MartinRC , et al. Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis. Journal of Surgical Research2007;143(1):164‐8. [MEDLINE: 17950088] ">Chagpar 2007</a>; <a href="./references#CD010308-bbs2-0005" title="MorganrothPA , GelfandJM , JambusariaA , MargolisDJ , MillerCJ . A randomized, double‐blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs micrographic surgery for skin cancers. Journal of the American Academy of Dermatology2009;60(3):444‐52. [EMBASE: 2009076713] ">Morganroth 2009</a>). </p> <section id="CD010308-sec-0077"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies that were randomised controlled trials were unclear if they included participants with melanoma in situ (<a href="./references#CD010308-bbs2-0006" title="AmatettiM , ProiettoG , PaoliniA , FelicianiC , CazzatoC , AmerioP . Adjuvant therapy with recombinant alpha‐interferon in non metastatic melanoma [TERAPIA ADIUVANTE CON INTERFERON‐ALFA RICOMBINANTE NEL MELANOMA CUTANEO]. Giornale Italiano di Dermatologia e Venereologia1994;129(6):31‐6. [EMBASE: 1994345755] ">Amatetti 1994</a>; <a href="./references#CD010308-bbs2-0007" title="FosterW , EsserA , MonheitG , HarmonC . A Prospective Randomized Study Comparing the Efficacy of Horizontal Mohs Tissue Processing to Vertical Breadloaf Tissue Processing in the Surgical Management of Superficial Melanoma. Journal of the American Academy of Dermatology2007;56(2 Suppl 2):AB145. [DOI: 10.1016/j.jaad.2006.10.672] ">Foster 2007</a>). One of these studies compared efficacy of horizontal Mohs tissue processing to vertical breadloaf tissue processing in the surgical management of superficial melanoma (<a href="./references#CD010308-bbs2-0007" title="FosterW , EsserA , MonheitG , HarmonC . A Prospective Randomized Study Comparing the Efficacy of Horizontal Mohs Tissue Processing to Vertical Breadloaf Tissue Processing in the Surgical Management of Superficial Melanoma. Journal of the American Academy of Dermatology2007;56(2 Suppl 2):AB145. [DOI: 10.1016/j.jaad.2006.10.672] ">Foster 2007</a>), and the other studied adjuvant therapy with recombinant alpha‐interferon in non‐metastatic melanoma (<a href="./references#CD010308-bbs2-0006" title="AmatettiM , ProiettoG , PaoliniA , FelicianiC , CazzatoC , AmerioP . Adjuvant therapy with recombinant alpha‐interferon in non metastatic melanoma [TERAPIA ADIUVANTE CON INTERFERON‐ALFA RICOMBINANTE NEL MELANOMA CUTANEO]. Giornale Italiano di Dermatologia e Venereologia1994;129(6):31‐6. [EMBASE: 1994345755] ">Amatetti 1994</a>). We contacted the contact authors of these studies in order to obtain more information, but they did not respond to our request. We have included them in the studies awaiting classification section and provide their known characteristics in the '<a href="./references#CD010308-sec-0135" title="">Characteristics of studies awaiting classification</a>' tables. Therefore, we were unable to include them in the current systematic review. </p> </section> <section id="CD010308-sec-0078"> <h5 class="title">Ongoing studies</h5> <p>Our search identified one ongoing study (<a href="./references#CD010308-bbs2-0008" title="NCT01720407 . Relevance of Imiquimod as Neo‐adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (ImiReduc). clinicaltrials.gov/show/NCT01720407 (accessed 20 March 2014). ">NCT01720407</a>), of which we provide details in the '<a href="./references#CD010308-sec-0136" title="">Characteristics of ongoing studies</a>' table. This is a randomised, parallel group, two‐arm, open label trial in active recruitment status. The aim of this study is to assess the relevance of imiquimod as neoadjuvant treatment to reduce excision size and the risk of intralesional excision in LM of the face. This study includes participants with LM of the face or neck, histologically confirmed by biopsy. Group A is treated with imiquimod (5 times per week) applied to and extending 1 cm beyond the lesion for a period of 4 weeks, and group B, with vehicle (5 times per week) applied to and extending 1 cm beyond the lesion for a period of 4 weeks. In both groups, surgery performed four weeks after the last application of the topical treatment follows local treatment. The primary outcome of this study is margin of resection. An at least 5 mm healthy tissue margin beyond lesion periphery defines successful resection with proper margins. This study started on October 2012, and MEDA Pharma GmbH &amp; Co. KG sponsors it. </p> </section> </section> </section> <section id="CD010308-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>We categorised judgements in order to indicate a low, high, or unclear risk of bias. The 'Risk of bias' graph (<a href="#CD010308-fig-0002">Figure 2</a>) summarises the results, in addition to the 'Risk of bias' table within the '<a href="./references#CD010308-sec-0133" title="">Characteristics of included studies</a>' table. </p> <div class="figure" id="CD010308-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD010308-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD010308-sec-0080"> <h4 class="title">Allocation</h4> <section id="CD010308-sec-0081"> <h5 class="title">Randomisation</h5> <p>We deemed the risk of selection bias from the random sequence generation as low; this is because the study used a 1:1 random number table for 2 interventions generated by the clinical trials office at the institution. </p> </section> <section id="CD010308-sec-0082"> <h5 class="title">Allocation</h5> <p>We initially judged the risk of selection bias from allocation concealment as unclear since authors did not report on this. However, contact with the study authors clarified that the study used a centralised service, so we deemed the risk of selection bias from allocation concealment as low. </p> </section> </section> <section id="CD010308-sec-0083"> <h4 class="title">Blinding</h4> <p>We judged the risk of bias as high since this was an open label trial and study participants, medical staff, and study staff were not blinded after the assignment was made. The study authors reported that blinding was not possible because of the nature of the study. However, a vehicle (placebo) treatment could have been used instead of tazarotene in the group that received imiquimod monotherapy. Further, blinded outcome assessment is usually possible for pathologists and clinical assessors. </p> </section> <section id="CD010308-sec-0084"> <h4 class="title">Incomplete outcome data</h4> <p>We judged the risk of bias as high because 5/46 participants from the imiquimod‐alone group and 7/44 participants from the imiquimod‐tazarotene group withdrew consent or dropped out because of adverse effects. The study partially provided reasons. The study did not report intention‐to‐treat analysis. </p> </section> <section id="CD010308-sec-0085"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of bias as low since the study reported all prespecified outcomes. The corresponding author of the study, Dr Hyde, provided us with all the data needed to evaluate it. </p> </section> <section id="CD010308-sec-0086"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010308-sec-0087"> <h5 class="title">Definition of incomplete response</h5> <p>We judged the risk of bias as low since the study clearly reported definition of incomplete response, which we deemed sufficient. </p> </section> <section id="CD010308-sec-0088"> <h5 class="title">Similarity of groups at baseline</h5> <p>We judged the risk of bias as unclear. Although we deemed the randomisation process sufficient and correct, the study authors did not present important baseline characteristics of the two groups, such as size of lesions, which could be potential confounding variables. </p> </section> <section id="CD010308-sec-0089"> <h5 class="title">Method and duration of follow up</h5> <p>We judged the risk of bias regarding duration of follow‐up period as low as we deemed the follow‐up period adequate (mean was 42 months). </p> <p>We judged the risk of bias regarding method of follow up for the initial five months as low as we deemed the method of follow up for this time period sufficient. </p> <p>The original article did not report the method of follow up after the initial five months (after surgery). The corresponding author of the study, Dr Mark Hyde, kindly provided additional data about this. He reported that follow up was done in clinic where possible. For those participants who did not come back to clinic, researchers made phone calls and asked them if they had seen another dermatologist or asked them to look at the scar and tell them if they saw any pigment in or around the scar. Unfortunately, Dr Hyde did not have records to tell us how many came back to clinic and how many follow‐ups were completed by phone. We therefore judged the risk of bias regarding method of follow up after the initial five months as high and deemed the method insufficient. </p> </section> <section id="CD010308-sec-0090"> <h5 class="title">Definition of local recurrence</h5> <p>We judged the risk of bias regarding definition of local recurrence as high. The study authors did not report the definition of local recurrence. The corresponding author of the study, Dr Hyde, was unable to provide any further information. </p> </section> </section> </section> <section id="CD010308-sec-0091"> <h3 class="title" id="CD010308-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD010308-tbl-0001"><b>Summary of findings for the main comparison</b> Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</a> </p> <p>We provided data in the <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a> for the primary and secondary outcomes. </p> <p>Imiquimod 5% cream with tazarotene 0.1% gel is the 'combination' therapy and is compared with imiquimod 5% cream alone, which is referred to as the 'monotherapy'. </p> <section id="CD010308-sec-0092"> <h4 class="title">Primary outcomes</h4> <section id="CD010308-sec-0093"> <h5 class="title">1. Histological or clinical complete response rate</h5> <p>This outcome was measured at five months, which fits our classification of short‐term (up to one year). The study authors reported that in the imiquimod monotherapy group, 27 out of 41 (65%) participants who reached the end point of the study had complete histological response. In the combination group (imiquimod with tazarotene), 29 out of 37 participants (78%) who reached the intended treatment duration had complete histological response. We contacted the corresponding author to obtain information regarding the participants who dropped out, and he kindly gave us access to primary data. </p> <p>We employed intention‐to‐treat analysis, characterising all participants who dropped out as treatment failures or not complete responders. We decided to do so taking into account the nature of the disease under investigation. Twenty‐nine out of 44 participants (66%) treated with imiquimod and tazarotene and 27 out of 46 participants (59%) treated with imiquimod monotherapy had complete clearance at 5 months. The difference was not statistically significant (risk ratio (RR) 1.12, 95% confidence interval (CI) 0.81 to 1.55, P value = 0.48; <a href="./references#CD010308-fig-0003" title="">Analysis 1.1</a>). </p> <p>We also employed analysis only for the participants who finished the study, as it had been reported by the study authors. Results did not show a statistically significant difference between groups (combination therapy versus monotherapy). Τhe complete response RR (risk ratio) was 1.19 (95% CI 0.90 to 1.57, P value = 0.22; <a href="./references#CD010308-fig-0004" title="">Analysis 1.2</a>). </p> <p>We carefully analysed the primary data that Dr Hyde provided. Of the five participants who dropped out from the imiquimod monotherapy group, three never started the treatment and withdrew consent. The other two started the topical treatment but did not finish it. These last two participants had complete response after subsequent surgery. From the seven participants who dropped out of the combination group, four had complete response; for one participant, data were missing; and the other two did not have a complete response. After evaluation of the data and taking into account the nature of the disease, we decided not to impute these data in any analysis. </p> <p>Because we identified only one study with a modest number of participants, we graded the quality of the evidence as low. See <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD010308-sec-0094"> <h5 class="title">2. Total number of acute and short‐term (up to one year) treatment‐related adverse events </h5> <p>The protocol of <a href="./references#CD010308-bbs2-0001" title="HydeMA , HadleyML , Tristani‐FirouziP , GoldgarD , BowenGM . A Randomized Trial of the Off‐Label Use of Imiquimod, 5%, Cream with vs without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions. Archives of Dermatology2012;148(5):592‐6. [MEDLINE: 22431716] ">Hyde 2012</a> did not include overall treatment‐related adverse events from non‐surgical or surgical interventions, but it did include total inflammation score (inflammatory response) (see below: Secondary outcome 9: Inflammatory response). Although this outcome can be considered as a treatment‐related adverse event, it is also an outcome that has been suggested to be associated with the efficacy of local treatment with imiquimod. </p> </section> </section> <section id="CD010308-sec-0095"> <h4 class="title">Secondary outcomes</h4> <section id="CD010308-sec-0096"> <h5 class="title">1. Clinical or histological local recurrence rate</h5> <p>The study did not report any recurrences in the mean follow‐up period of 42 months. This fits with our classification of medium‐term (from year one up to year five). The study authors reported that prior to initiation of topical treatment (in order to avoid the risk of treating invasive lentigo maligna melanoma (LMM)) with topical imiquimod, all visible signs of LM were removed using a shave excision at the first visit. The corresponding author of the study informed us that there were eight people who had died of unrelated causes during this follow‐up period. Of those who dropped out of the study, follow‐up data were available for only one person. </p> </section> <section id="CD010308-sec-0097"> <h5 class="title">2. Time to complete histological or clinical clearance (for surgical and non‐surgical treatments) </h5> <p>The study did not measure or report this outcome.</p> </section> <section id="CD010308-sec-0098"> <h5 class="title">3. Time to histological or clinical local recurrence</h5> <p>The study did not measure or report this outcome.</p> </section> <section id="CD010308-sec-0099"> <h5 class="title">4. Incidence of distal metastases</h5> <p>The study did not assess or report Incidence of distal metastases.</p> </section> <section id="CD010308-sec-0100"> <h5 class="title">5. Progression to invasive melanoma</h5> <p>One participant out of the 44 participants from the combination‐therapy group (imiquimod plus tazarotene) developed invasive melanoma (0.32 Breslow depth and Clark level III) at the treatment site in the 2‐month interval between topical therapy completion and surgery. This fits our classification of short‐term (up to one year). The imiquimod monotherapy group reported no cases of invasive melanoma. </p> </section> <section id="CD010308-sec-0101"> <h5 class="title">6. Short‐, medium‐, and long‐term participant satisfaction</h5> <p>The study did not measure or report this outcome.</p> </section> <section id="CD010308-sec-0102"> <h5 class="title">7. Treatment‐related quality of life</h5> <p>The study did not measure or report this outcome.</p> </section> <section id="CD010308-sec-0103"> <h5 class="title">8. Discontinuation of treatment because of harms</h5> <p>One participant out of 46 (2.2%) in the imiquimod monotherapy group dropped out due to excessive inflammation (inflammation grade of 3) before the cessation of topical treatment (first 3 months). Six out of 44 participants (13.7%) dropped out due to adverse events before the cessation of topical treatment (first 3 months). The result of the comparison was not statistically significant (RR 6.27, 95% CI 0.79 to 50.02, P value = 0.08; <a href="./references#CD010308-fig-0005" title="">Analysis 1.3</a>). </p> <p>As this single study was insufficiently powered to document a real difference between the two groups, we graded the quality of the evidence as low. See <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD010308-sec-0104"> <h5 class="title">9. Inflammatory response</h5> <p>The study graded inflammatory response by the maximum intensity observed using a scale of zero to three (none: no inflammation; one: pink; two: red; three: presence of erosions, oozing, or eschar). The study authors reported that participants in the combination therapy group had a significantly higher overall inflammation score (mean = 2.3) than those in the monotherapy group (mean = 1.8). These values correspond to the participants who reached the end point of the trial. The study authors did not report on the participants who dropped out; however, we contacted them and obtained primary data for all participants. </p> <p>We first analysed the primary data of the participants who completed the study. Mean overall inflammation score for the monotherapy group was 1.738 and standard deviation was 0.989 (41 participants). Mean overall inflammation score for the combination group was 2.297 and standard deviation was 0.9 (37 participants). Difference in overall inflammation score between the 2 groups was significant (mean difference (MD) 0.56, 95% CI 0.14 to 0.98, P value = 0.009; <a href="./references#CD010308-fig-0006" title="">Analysis 1.4</a>). Mean overall inflammation score was significantly higher in the combination group compared to the monotherapy group. </p> <p>We also analysed all data for all participants regarding the inflammatory response. For three participants from the imiquimod monotherapy group, no topical treatment was initiated and no data recorded. We decided to exclude these three participants from the analysis. For the other 43 participants, we imputed the highest grade of inflammation recorded per case. Mean inflammation score was 1.7 and standard deviation was 1 in the monotherapy group (43 participants). Regarding the 44 participants from the combination group, we imputed the highest grade of inflammation recorded per case. Mean inflammation score was 2.3, and standard deviation was 0.93 (44 participants). Difference in overall inflammation score between the 2 groups was statistically significant (MD 0.6, 95% CI 0.2 to 1, P value = 0.004; <a href="./references#CD010308-fig-0007" title="">Analysis 1.5</a>). Mean overall inflammation score was significantly higher in the combination group compared with the monotherapy group. </p> <p>Given that for one of the groups the mean score (2.29) is close to the maximum (3), these methods that are suitable for normally distributed data might under‐ or over‐estimate the mean difference (<a href="./references#CD010308-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Because we had contacted the study authors and the original data values were available, we re‐analysed the inflammation scores using non‐parametric methods suitable for ordinal data (Mann‐Whitney U test). Mann‐Whitney U test ‐ using ranks ‐ yielded an identical P value (P value = 0.004), with the mean difference method supported by Review Manager (<a href="./references#CD010308-bbs2-0065" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Even though this difference is most probably real, because we identified only one study with a modest number of participants, we graded the quality of the evidence as low. See <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We conducted a posthoc analysis regarding the number of lesions that achieved a grade two or three inflammatory response. Analysis of all primary data indicated that 26 of the 44 lesions in the monotherapy group achieved a grade 2 or 3 inflammatory response. In the combined therapy group, 36 of 44 lesions achieved a grade 2 or 3 inflammatory response. The difference between the 2 groups was statistically significant in favour of monotherapy (RR 1.38, 95% CI 1.04 to 1.84, P value = 0.02; <a href="./references#CD010308-fig-0008" title="">Analysis 1.6</a>). </p> <p>As we only identified one study with a modest number of participants, we graded the quality of the evidence as low. See <a href="./full#CD010308-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010308-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010308-sec-0105"></div> <section id="CD010308-sec-0106"> <h3 class="title" id="CD010308-sec-0106">Summary of main results</h3> <p>This systematic review tried to summarise all available interventions for the treatment of melanoma in situ, including lentigo maligna. We identified only one randomised, single centre, open label, parallel group, two‐arm, controlled trial. The trial treated 44 participants with imiquimod 5% cream plus tazarotene 0.1% gel (combination therapy group) and 46 participants with Imiquimod 5% cream (monotherapy group). </p> <p>Regarding our primary outcome 'Histological or clinical complete response rate', there was no statistically significant difference (RR 1.12, 95% CI 0.81 to 1.55, P value = 0.48, intention‐to‐treat (ITT) analysis) between the combination (66%) and monotherapy groups (59%). The best complete response rate was 78% for the combination group and 66% for the monotherapy group. </p> <p>With regard to our secondary outcomes, discontinuation of treatment because of harms was not statistically significant. Inflammatory response was reported as mean inflammatory score; this is an interesting outcome that is a treatment‐related adverse event. However, it has also been suggested that it could be an outcome related to efficacy of imiquimod. Mean overall inflammation score was statistically significantly higher in the combination group. Interestingly, although combination therapy exhibited a significantly higher degree of inflammation, this did not translate to a significant increase in the completed histological response rate. This suggests that the quantity of inflammation may not be a factor associated with increased efficacy. Enhancing drug penetration with tazarotene did not increase the complete response rate but did lead to substantially more inflammation. One person out of the 44 participants from the combination therapy group developed invasive melanoma. This emphasises the need for close, adequate, and structured follow up at predefined periods for people treated with imiquimod as monotherapy. In the mean follow‐up period of 42 months, the study reported no local recurrences. Previously published recurrence rates for stage excision alone are approximately 6% (<a href="./references#CD010308-bbs2-0014" title="BubJL , BergD , SleeA , OdlandPB . Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5‐year follow‐up. Archives of Dermatology2004;140(5):552‐8. [MEDLINE: 15148099] ">Bub 2004</a>; <a href="./references#CD010308-bbs2-0048" title="LeeMR , RymanWJ . Treatment of lentigo maligna with total circumferential margin control using vertical and horizontal permanent sections: a retrospective study. Australasian Journal of Dermatology2008;49(4):196‐201. [MEDLINE: 18855780] ">Lee 2008</a>; <a href="./references#CD010308-bbs2-0077" title="WallingHW , ScuphamRK , BeanAK , CeilleyRI . Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. Journal of the American Academy of Dermatology2007;57(4):659‐64. [MEDLINE: 17870430] ">Walling 2007</a>). </p> <p>Whether or not addition of imiquimod as neoadjuvant treatment can decrease local recurrence rate remains a question that future studies should properly address. </p> </section> <section id="CD010308-sec-0107"> <h3 class="title" id="CD010308-sec-0107">Overall completeness and applicability of evidence</h3> <p>This systematic review identified only one study eligible for inclusion and one ongoing study. It is unlikely that the results of the only included study can facilitate clinicians in making evidence‐based treatment decisions. Important outcomes for the evaluation of imiquimod as neoadjuvant treatment, such as reduction of excision size, morbidity, and quality of life, are not properly addressed, although these may be important clinically relevant outcomes. There is insufficient evidence to support or refute the addition of tazarotene to imiquimod as adjuvant therapy. Since tazarotene is one of the strongest topical retinoids (with only isotretinoin 0.05% gel being stronger), addition of any other retinoid is not recommended and is likely to highly increase inflammation and dropout of patients from treatment with no significant efficacy gain. </p> </section> <section id="CD010308-sec-0108"> <h3 class="title" id="CD010308-sec-0108">Quality of the evidence</h3> <p>There is a paucity of randomised controlled trials (RCTs) and high‐quality evidence for the treatment of melanoma in situ and lentigo maligna. Appropriate studies of the most important clinically relevant outcomes, such as recurrence rate; reduction of excision size with the use of neoadjuvant treatments; morbidity; and participant‐rated outcomes, such as satisfaction rate and quality of life, are needed. Our included study was a single centre, open label, parallel group trial with only 90 participants allocated in 2 arms, thus, not adequately powered; no sample size calculation according to any specific clinically relevant outcome was made. The comparisons of interventions in the study were relevant to this disease, but do not cover the range of outcomes this review is aimed at. </p> <p>We downgraded all the outcomes we examined by two levels to reflect the fact that the single eligible study by <a href="./references#CD010308-bbs2-0001" title="HydeMA , HadleyML , Tristani‐FirouziP , GoldgarD , BowenGM . A Randomized Trial of the Off‐Label Use of Imiquimod, 5%, Cream with vs without Tazarotene, 0.1%, Gel for the Treatment of Lentigo Maligna, Followed by Conservative Staged Excisions. Archives of Dermatology2012;148(5):592‐6. [MEDLINE: 22431716] ">Hyde 2012</a> was subject to a high risk of bias due to lack of blinding, partially incomplete outcome data, and method of follow up. Overall, we judged the evidence to be of low quality, meaning that future studies will modify confidence in the estimate of effect, which in turn could be reversed. </p> </section> <section id="CD010308-sec-0109"> <h3 class="title" id="CD010308-sec-0109">Potential biases in the review process</h3> <p>We assessed risk of bias as low for random sequence generation and selective reporting, definition of incomplete response, and duration of follow up. There was no blinding of participants, personnel, or outcome assessors; therefore, we judged blinding as at high risk of bias. Analysis was not intention‐to‐treat, leading to a high risk of incomplete outcome data. We deemed method of follow up after the initial five months and definition of local recurrence as at high risk of bias. These parameters are of high significance. The study did not report information on similarity of groups at baseline for important confounding variables such as the size of the lesion. </p> <p>We need to mention several limitations of this systematic review. "As with any [review] there is the potential for publication bias to over‐estimate differences in outcomes if studies identifying such differences are more likely to be published in peer‐reviewed journals" (<a href="./references#CD010308-bbs2-0071" title="SladdenMJ , BalchC , BarzilaiDA , BergD , FreimanA , HandisideT , et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD004835.pub2] ">Sladden 2009</a>). This review has the limitation of solely depending on a single study to detect real differences in outcomes. The total number of participants recruited in the included study was not based on a sample size calculation, and the study was insufficiently powered to rule out clinically relevant differences. </p> <p>We made a substantial effort to obtain information on studies that might include a subset of people with melanoma in situ or lentigo maligna melanoma (LMM). We identified two studies that might be eligible for inclusion in this review, but it was unclear if they included participants with melanoma in situ or LMM (<a href="./references#CD010308-bbs2-0006" title="AmatettiM , ProiettoG , PaoliniA , FelicianiC , CazzatoC , AmerioP . Adjuvant therapy with recombinant alpha‐interferon in non metastatic melanoma [TERAPIA ADIUVANTE CON INTERFERON‐ALFA RICOMBINANTE NEL MELANOMA CUTANEO]. Giornale Italiano di Dermatologia e Venereologia1994;129(6):31‐6. [EMBASE: 1994345755] ">Amatetti 1994</a>; <a href="./references#CD010308-bbs2-0007" title="FosterW , EsserA , MonheitG , HarmonC . A Prospective Randomized Study Comparing the Efficacy of Horizontal Mohs Tissue Processing to Vertical Breadloaf Tissue Processing in the Surgical Management of Superficial Melanoma. Journal of the American Academy of Dermatology2007;56(2 Suppl 2):AB145. [DOI: 10.1016/j.jaad.2006.10.672] ">Foster 2007</a>), so this makes our review somewhat incomplete. We contacted the study authors to obtain further information, but to date, they have not responded, so we have detailed these in the '<a href="./references#CD010308-sec-0135" title="">Characteristics of studies awaiting classification</a>' tables. </p> </section> <section id="CD010308-sec-0110"> <h3 class="title" id="CD010308-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>One systematic review, <a href="./references#CD010308-bbs2-0031" title="FogartyGB , HongA , ScolyerRA , LinE , HayduL , GuiteraP , et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. British Journal of Dermatology2014;170(1):52‐8. [MEDLINE: 24032599] ">Fogarty 2014</a>, tried to summarise the published evidence for the use of radiotherapy in the treatment of LM, focusing on technical aspects in order to develop the best evidence‐based radiotherapy protocol. The authors included any type of studies and could identify only retrospective case series. They concluded that there is a lack of standardisation of the studies, and overall, they could not identify the optimum parameters for radiotherapy. </p> <p>A review of treatments for LM tried to comprehensively review available evidence (<a href="./references#CD010308-bbs2-0055" title="McLeodM , ChoudharyS , GiannakakisG , NouriK . Surgical Treatments for Lentigo Maligna: A Review. Dermatologic Surgery2011; Vol. 37, issue 9:1210‐28. [MEDLINE: 21631635] ">McLeod 2011</a>). The authors employed a specific search strategy with prespecified key search terms, which did not have any restrictions regarding the type of studies, and they included all investigational studies of any design, both prospective and retrospective. They found a number of studies: 12 examining staged surgical excision, 9 using Mohs micrographic surgery, 6 investigating cryosurgery, 22 investigating imiquimod, 7 using lasers, 9 investigating radiation therapy, and 2 investigating electrosurgery and curettage. The authors presented tables with important outcomes and variables. They concluded that staged surgical excision and Mohs micrographic surgery are linked with the lowest recurrence rates for LM and that cryotherapy and radiation therapy may be contemplated as the options for treatment of LM in people who cannot endure surgery (<a href="./references#CD010308-bbs2-0055" title="McLeodM , ChoudharyS , GiannakakisG , NouriK . Surgical Treatments for Lentigo Maligna: A Review. Dermatologic Surgery2011; Vol. 37, issue 9:1210‐28. [MEDLINE: 21631635] ">McLeod 2011</a>). They also suggested that imiquimod may have a future role to play in the treatment of LM. </p> <p>Another review summarised the treatment options specifically for melanoma in situ (<a href="./references#CD010308-bbs2-0027" title="EricksonC , MillerSJ . Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. International Journal of Dermatology2010;49(5):482‐91. [MEDLINE: 20534080] ">Erickson 2010</a>). The authors employed a specific search strategy that did not restrict the types of studies included and presented tables for many important variables. They concluded that "topical imiquimod therapy appears to provide relatively low cure rates" and should be used with extreme caution. "Radiation therapy may be a useful second‐line therapy if surgery is contraindicated". They clearly suggest that "excisional surgery is an appropriate therapy for clinically well‐defined melanomas in situ. However, margins larger than 5 mm may be required when treating larger or indistinct lesions." </p> <p>We excluded from this systematic review all of the studies (except one) included in the aforementioned reviews because they were case series, retrospective, and uncontrolled studies. These types of studies were not eligible for inclusion in this systematic review, since we restricted the predefined inclusion criteria to randomised controlled trials. Our review and all of the aforementioned three reviews reported limited evidence. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010308-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD010308-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD010308-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 1 Primary outcome: Histological complete response (ITT)." data-id="CD010308-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 1 Primary outcome: Histological complete response (ITT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 2 Primary outcome: Histological complete response (available‐case analysis)." data-id="CD010308-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 2 Primary outcome: Histological complete response (available‐case analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 3 Secondary outcome: Discontinuation of treatment because of harms." data-id="CD010308-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 3 Secondary outcome: Discontinuation of treatment because of harms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 4 Secondary outcome: Inflammatory response (overall Inflammation score) for participants who finished study." data-id="CD010308-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 4 Secondary outcome: Inflammatory response (overall Inflammation score) for participants who finished study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 5 Secondary outcome: Inflammatory response (overall Inflammation score) for all participants." data-id="CD010308-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 5 Secondary outcome: Inflammatory response (overall Inflammation score) for all participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010308-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/urn:x-wiley:14651858:media:CD010308:CD010308-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_t/tCD010308-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 6 Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3)." data-id="CD010308-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna, Outcome 6 Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/media/CDSR/CD010308/image_n/nCD010308-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010308-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with melanoma in situ, including lentigo maligna<br/> <b>Settings:</b> 1 academic centre in the US<br/> <b>Intervention:</b> imiquimod 5% cream with tazarotene 0.1% gel<br/> <b>Comparison:</b> imiquimod 5% cream alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Imiquimod 5% cream alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Imiquimod 5% cream with tazarotene 0.1% gel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome:</b> </p> <p><b>Histological complete response (intention‐to‐treat)</b> <br/> No residual LM in staged excision 2 months post‐treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>587 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>657 per 1000</b> <br/> (475 to 910) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (0.81 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome:</b> </p> <p><b>Histological complete response ( available‐case analysis)</b> <br/> No residual LM in staged excision 2 months post‐treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>659 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> <br/> (593 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.9 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Discontinuation of treatment because of harms</b> <br/> Discontinuation of treatment due to adverse effects </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> <br/> (17 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.27</b> <br/> (0.79 to 50.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Inflammatory response (number of lesions with grade 2 or 3)</b> <br/> Grade 2 or 3 Inflammation² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>591 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>815 per 1000</b> <br/> (615 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b> <br/> (1.04 to 1.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Secondary outcome:</b> </p> <p><b>Inflammatory response</b> </p> <p><b>(overall Inflammation score) for all participants</b> <br/> Mean grade of inflammation in each group² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall inflammation score (inflammatory response) for all participants in the intervention groups was <b>0.60 higher</b> <br/> (0.2 to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>GRADE = Grading of Recommendations Assessment, Development and Evaluation.<br/> LM = lentigo maligna.<br/> ¹Published evidence is limited to a single randomised trial.<br/> ²(0 indicates no inflammation; 1, pink; 2, red; and 3, the presence of erosions, oozing, or eschar). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Imiquimod 5% cream with tazarotene 0.1% gel compared with Imiquimod 5% cream alone for melanoma in situ, including lentigo maligna</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010308-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Medical term</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Explanation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intraepidermal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>something confined within the epidermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Preinvasive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a malignant tumour that remains constricted in the epithelium, while the dermo‐epidermal junction preserves its integrity </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eschar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a dry scab or slough formed on the skin as a result of a burn or by the action of a corrosive or caustic substance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invasive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a malignant tumour that breaks the dermo‐epidermal junction and invades the dermis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lentigo maligna</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a subtype of preinvasive intraepidermal melanoma, associated specifically with chronic solar exposure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vehicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>an excipient or a menstruum, a substance, usually without therapeutic action, used as a medium to give bulk for the administration of medicines </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Apoptosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a genetically directed process of cell self‐destruction that is marked by the fragmentation of nuclear DNA. It is activated either by the presence of a stimulus or removal of a suppressing agent or stimulus, and is a normal physiological process eliminating DNA‐damaged, superfluous, or unwanted cells. It is a synonym for programmed cell death </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Actinic keratosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>rough, scaly macule or patch of skin that it is considered precancerous and is associated with chronic sun exposure </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lentigo senilis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a flat brownish, pigmented spot on the skin, due to increased deposition of melanin and an increased number of melanocytes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Seborrheic keratosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a benign skin tumour that occurs singly or in clusters on the surface of the skin, is usually light to dark brown or black in colour, and typically has a warty texture often with a waxy appearance </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patch</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a greater than 1 cm circumscribed area of discolouration on the skin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a small protein released by cells that has a specific effect on the interactions between cells, on communications between cells, or on the behavior of cells </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Innate immunity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>immunity that occurs naturally as a result of a person's genetic constitution or physiology and does not arise from a previous infection or vaccination </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the concealment of group assignment ‐ to either the treatment or control group ‐ from the knowledge of participants, investigators in a clinical trial, or both </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>aggregates of tumour cells</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of medical terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/full#CD010308-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010308-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: Histological complete response (ITT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Primary outcome: Histological complete response (available‐case analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secondary outcome: Discontinuation of treatment because of harms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Secondary outcome: Inflammatory response (overall Inflammation score) for participants who finished study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Secondary outcome: Inflammatory response (overall Inflammation score) for all participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Imiquimod 5% cream with versus without tazarotene 0.1% gel for the treatment of lentigo maligna</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010308.pub2/references#CD010308-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010308.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD010308-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD010308-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010308-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD010308-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010308\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010308\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010308\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010308\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010308\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tlnpj831&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010308.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010308.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010308.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010308.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010308.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727037991"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010308.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727037995"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010308.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea24bbb29f401',t:'MTc0MDcyNzAzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 